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SECTION I: BIOCHEMICAL, STRUCTURAL, AND DRUG DESIGN 
STUDIES OF NOROVIRUS PROTEASE 
CHAPTER 1: NOROVIRUS INTRODUCTION  
1.1 Norovirus classification and epidemiology 
Noroviruses are non-enveloped single-stranded positive-sense RNA viruses belonging to the 
Caliciviridae family and are the leading cause of viral gastroenteritis worldwide(6). Noroviruses are divided 
into seven genogroups (GI-GVII) based on the complete amino acid sequence of the VP1 capsid protein(7) 
and are further divided into genotypes. GI noroviruses are divided into nine genotypes, all of which infect 
humans(7). GII, consisting of 22 genotypes, mainly infect humans; however, three genotype of GII (GII.11, 
GII.18, and GII.19) have been shown to infect pigs(7). GIII contains three genotypes and infect cow and 
sheep. GIV contains two genotypes: GIV.1 infects humans and GIV.2 infects canines and felines(7). GV 
contains two genotypes and infects mice and rats(7). GVI (two genotypes) and GVII infect canine 
species(7).  
GI, GII, and GIV have all been shown to cause infections in humans with GI and GII noroviruses 
predominantly associated with outbreaks (8). In the United States from 2009 to 2013, a total of 3,960 
norovirus outbreaks were reported and classified as either GI (11%) or GII (89%) noroviruses – a majority 
of which (72%) were caused by GII.4 strains(8). GII.4 noroviruses are also thought to be responsible for 
the majority (62%) of worldwide outbreaks(9). Outbreaks tend to occur in semi-closed communities 
including hospitals, schools, cruise ships, and long-term-care facilities(7) (Fig. 1.1). 
Norovirus infections can be transmitted orally via contact with fecal matter, aerosolized vomitus, 
or contaminated surfaces, food, or water(7). Symptoms of the viral infection include severe vomiting, 
diarrhea, nausea, abdominal cramps, and fever. While healthy individuals usually experience symptoms for 
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48 hours or less, children and elderly patients are at higher risk for developing long-term or even fatal 
infections(10-12). In addition, norovirus infections pose a significant risk to immunocompromised patients 
as these patients are at risk for prolonged disease which requires fluid replacement and supportive 
care(11,13).  
As a result, it is estimated that each year in the United States there are 19-20 million cases, leading 
to roughly 800 deaths and 71,000 hospitalizations and a total cost of ~2 billion US dollars(14,15). On a 
global scale, an estimated 677 million norovirus infections occur each year leading to 213,000 deaths 
(16,17)and an estimated total cost of ~64 billion US dollars/year(18).  
1.2 Norovirus tropism 
It has long been thought, due to the extreme gastrointestinal symptoms presented, that norovirus 
would replicate in intestinal epithelial cells (6). Attempts to culture norovirus in vitro have been shown to 
be successful in human B cell lines as well as stem-cell-derived intestinal enteroid cells suggesting a dual 
tropism for immune and intestinal epithelial cells(19-21). Biopsies from norovirus infected patients also 
suggest dual tropism of noroviruses in vivo (22). 
Health Care Facility
63%
Restaurant/Banquet 
Facility
22%
School/Day-Care
6%
Private Residence
2%
Other/multiple 
settings
7%
NOROVIRUS EXPOSURE SETTINGS
Figure 1.1. Most common norovirus exposure settings. Setting of norovirus outbreaks reported through the National 
Outbreak reporting System (NORS) from 2009-2012 and documented by the U.S. Centers for Disease Control and Prevention 
(CDC): https://www.cdc.gov/norovirus/setting-outbreaks.html   
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1.3 Norovirus genome organization 
The norovirus genome consists of positive-sense, single-stranded RNA approximately 7.7 kb 
long(6). The genome is divided into three open reading frames (ORFs) (23) as shown in Figure 1.2. ORF1 
encodes for the viral non-structural (NS) proteins NS1-NS7. ORF1 is synthesized as a polyprotein and is 
cleaved by the viral protease, NS6, to release mature proteins NS1/2, the NTPase/RNA helicase (NS3), 
NS4, VPg (NS5), and the viral RNA-dependent RNA polymerase (NS7)(24). ORF2 encodes for the major 
capsid protein, VP1, and ORF3 encodes the minor capsid protein, VP2(6,24). 
1.4 Norovirus life cycle 
The first step in the norovirus life cycle involves norovirus virus-like particles (VLPs) attaching to 
a cell surface receptor. Histo blood group antigens (HBGAs), linked to lipids such as glycosphingolipids 
(GSLs), galactosylceramide, or gangliosides, have been demonstrated to serve as the attachment receptor 
for norovirus particles(25-32). Interestingly, individuals that express active α(1,2) fucosyltransferase 
(FUT2) enzyme – known as secretors – appear to be more susceptible to norovirus infections (25-29). FUT2 
attaches fucose to HBGAs via a α1,2 linkage (6). Norovirus VLP binding to HBGA-GSLs leads to the 
formation of GSLs clusters which form lipid microdomains causing invagination of the cell membrane(33). 
Endocytosis of norovirus VLP remains unclear but may depend on dynamin II, ceramide, and cholesterol, 
while acting independently of clathrin, caveolin, or pH (6,34-36). 
Following entry into the host cell, VPg-linked RNA genome is translated by host machinery; the 
host machinery is thought to be recruited by VPg, which is a necessary protein for infectivity (24,37). ORF2 
Figure 1.2. Norovirus genome organization. 
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and ORF3 are translated from subgenomic RNA. ORF1 is translated as a polyprotein, which is then cleaved 
by the viral protease, NS6, to release the viral NS proteins. The NS proteins, VP1, and VP2, co-localize 
with the viral RdRp (NS7) to form the replication complex (38,39). The mechanisms involving viral 
assembly remain unclear. Processes involved in the exit of newly formed virions also remain unclear; 
however, intestinal biopsies from norovirus infected patients reveal an accumulation of apoptotic epithelial 
cells, suggesting apoptosis may serve as an exit strategy (40-42).  
1.5 Norovirus vaccine development 
One strategy to prevent norovirus infections is the development of a norovirus vaccine. No vaccine 
has yet been approved; however, vaccine development has shown promise in pre-clinical animal models as 
well as human clinical trials. It has been shown that VLPs comprised of VP1 protein can induce an immune 
response (43,44). Norovirus vaccines comprising VLPs or VP1 replicon have proved successful in animal 
studies, immunizing chimpanzees(45) (18 months), gnotobiotic pigs(46) (28 days), or mice(47) (6 months) 
against future norovirus challenge. Additionally, GI.1 VLPs plus adjuvant reduced the prevalence of 
gastroenteritis (32% reduction) and incidence of infection (21% reduction) in human volunteers upon 
challenge with live virus three weeks after immunization(48). Interestingly, the presence of pre-challenge 
antibodies capable of blocking binding to HBGAs was correlated with protection against infection(48,49). 
1.6 Norovirus antiviral drug targets 
Currently there is no FDA approved norovirus-specific antiviral agent. Viral enzymes including 
the viral RdRp and viral protease have been identified as potential drug targets. The viral RdRp is an 
attractive drug target due to its essential role in the norovirus life cycle as well as the absence of homologous 
human proteins(50). 5-fluorouracil(51), 2-thiouridine and ribavirin(52), suramin-related compounds(53), 
2’-C-methylcytidine(54,55), and favipiravir(56) all may serve as suitable starting points for the 
development of norovirus RdRp inhibitors. The viral protease, another promising drug target, will be 
explored in sections 1.7 and 1.8. 
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Blocking norovirus binding and attachment to host HBGAs is another viable anti-norovirus 
strategy. Norovirus HBGA-binding sites are conserved – a molecule blocking the HBGA binding site and 
could provide beneficial anti-norovirus activity(50,57-59). Multiple HBGA binding site blockers have been 
identified(59-61). 
1.7 Norovirus protease 
As previously described in section 1.4, the ORF1 is synthesized as a polyprotein which is then 
cleaved by the virus’ NS6 protease to release mature proteins NS1/2, the NTPase/RNA helicase (NS3), 
NS4, VPg (NS5), and the viral RNA-dependent RNA polymerase (NS7)(24); glutamine/glycine (Q/G), 
glutamate/glycine (E/G), or glutamate/alanine (E/A) serve as cleavage site junctions (Fig. 1.2). The 
norovirus protease, a 3C-like protease (3CLpro), is a cysteine protease that adopts a chymotrypsin-like 
fold(62-66) (Fig. 1.3). The chymotrypsin-like fold consists of two domains, the N-terminal twisted β-sheet 
and C-terminal β-barrel. A cleft separates the two domains where the catalytic triad (His30, Glu54, and 
Cys139) is located. The catalytic triad is conserved between genogroups(3,41,65-70). Other highly 
conserved areas include the S1 substrate pocket (residues 134-138, and 157), the S2 pocket (residues 30, 
109, 112-113, and 158-159), the S4 pocket (residues 107, 118, 161, 166, 168), as well as residues which 
have been reported to contribute important hydrogen bonds to the substrate backbone (residues 110, 158, 
Figure 1.3. A) General structure of 
norovirus proteases. Norovirus 
proteases have two domains: The N-
terminus (Blue) is a twisted β-sheet, 
and the C-terminus is a β-barrel (Red). 
The catalytic triad is located in the cleft 
between the two domains. B) Surface 
representation of a homology model 
of the Minerva virus protease 
showing the substrate binding channel 
represented by a dashed line with each 
respective binding pocket individually 
colored (S1, S2, and S4). The catalytic 
triad is shown in red and the positively 
charged oxyanion hole that stabilizes 
the transition state is shown in dark 
blue. 
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and 160). Due to its essential role in the viral life cycle, the norovirus protease has become an attractive 
drug target.  
1.8 Norovirus protease inhibitors 
Recent advances facilitated by the discovery of the 3CLpro(63) and subsequent elucidation of its 
crystal structure(67,68), development of a FRET-based assay(2) and  replicon system(71) have allowed for 
structure-based design and evaluation of 3CLpro inhibitors. Norovirus proteases inhibitors are typically 
peptidomimetics mimicking the P4-P1 cleavage site residues attached to a c-terminal electrophilic warhead 
for covalent attachment to the catalytic Cys139. Covalent inhibitors containing an aldehyde(1,4,72-74) or 
bisulfite-adduct salt warhead(1,75) (the latter is thought to serve as a pro-drug to the aldehyde form). 
Additional warheads investigated include α-ketoamide(1,76), α-ketoheterocycle(76), or α-
hydroxyphosphonate(77) warheads(78). An active site directed peptide inhibitor with a propenyl-ethyl-
ester extension acting as a Michael-acceptor warhead has also been reported(3). In addition, macrocyclic 
compounds have also been evaluated against the norovirus protease (79-81). Much of this progress has been 
made with GI norovirus proteases, such as the Norwalk virus protease (GI.1) (68,71,72,78), Chiba virus 
protease (64,65), or Southampton virus protease (3,63), serving as the target. To date, the aforementioned 
norovirus protease inhibitors have proven efficacious in a biochemical assay (IC50 < 100 nM) (1,4,72,73,75-
78,82-84), as well as in vivo against the murine model of norovirus infection (EC50 = 80 nM) (4).  
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CHAPTER 2: COMPOUTATIONAL ANALYSIS OF HUMAN NOROVIRUS 
PROTEASES AS DRUG TARGETS 
2.1 Introduction 
Noroviruses are the leading cause of viral gastroenteritis (6) and are responsible for roughly 20 
million cases each year in the United States (14,15). Noroviruses are classified into seven genogroups (GI-
GVII) (7). GI, GII, and GIV noroviruses have been shown to infect humans; however, from 2009 to 2013 
in the United States, the majority (89%) of outbreaks were caused by GII noroviruses, 72% of which were 
specifically genogroup II genotype 4 (GII.4) noroviruses (8). Currently no anti-norovirus therapy has been 
approved for human use. However, the NS6 3C-like protease (3CLpro) has been a target for the 
development of norovirus protease inhibitors (1,4,72-81).   
 The design and development of norovirus 3CLpro inhibitors has largely been facilitated using GI 
norovirus proteases as the target despite the overwhelming prevalence of GII outbreaks (3,63-
65,68,71,72,78). This may be attributed to the development of a GI norovirus biochemical assay (2) and GI 
norovirus replicon system (71). However, there remains a relative dearth of information regarding GII 
norovirus proteases in the literature.  
In this study, a homology model of a GII.4 norovirus protease (Minerva virus) was created based 
on the x-ray crystal structure of the GI.1 norovirus protease (Norwalk virus). The GI.1 and GII.4 structures 
were analyzed and compared using molecular dynamics simulations and other computational techniques to 
evaluate the two different genogroups as targets for small-molecule inhibition. Based on the results 
presented here, a broad-spectrum spectrum norovirus protease inhibitor is likely a feasible option for drug 
design.  
2.2 Materials and Methods 
2.2.1 System Preparation 
Protein Data Bank entry 3UR6 (1) was used as the starting coordinates for the GI.1 norovirus 
protease. PDBID: 3UR6 is the 1.5 Å resolution structure of the apo Norwalk virus protease – a GI.1 
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norovirus protease. To date, no GII.4 norovirus protease structure exists. Therefore, a homology model of 
the GII.4 norovirus protease was built to establish starting coordinates for the GII.4 norovirus protease. The 
sequence corresponding to the NS6 protease from the GII.4 Minerva strain (Genbank accession no: 
EF684915, which corresponds to the 2006b variant of the Minerva virus) was submitted to the Swiss-Model 
server (85) using PDBID: 3UR6 as a template structure.   
The norovirus GI.1 and GII.4 models were prepared for molecular dynamics (MD) simulations 
using VMD v 1.9.2 (86). The models were placed in a 12 Å TIP3P (transferable intermolecular potential 
with 3-points) water box and the systems were neutralized by the addition of magnesium chloride.  
2.2.2 Energy minimization and molecular dynamics simulation 
Energy minimization and molecular dynamics were performed as previously described (87,88). 
Briefly, 20,000 steps of conjugate gradient energy minimization were performed prior to molecular 
dynamics. MD simulations were performed using NAMD v. 2.9 (89) and were carried out for 100 ns with 
a 2 fs time step. The trajectory files were updated every 10,000 steps, corresponding to every 20 ps. 
Simulations were performed in the NPT ensemble (the number of particles, the temperature, and the 
pressure are kept constant) and were carried out at a constant temperature of 310 K. The MD simulations 
were performed in parallel using the Wayne State University high performance computing Grid 
(www.grid.wayne.edu).  
2.2.3 Data analysis 
The trajectory files from NAMD, starting with the first frame post energy minimization, were 
loaded into VMD for analysis. The root mean square deviation (RMSD) trajectory tool was used to calculate 
the overall flexibility for each protease, GI.1 and GII.4. Per-residue RMSD, root mean square fluctuation 
(RMSF), and solvent accessible surface area (SASA) were calculated using the timeline tool in VMD.  
In addition, the substrate binding region for GI.1 and GII.4 norovirus proteases were analyzed for 
druggability, hydrophobicity, hydrophilicity, propensity for hydrogen-bond donors or acceptors, and 
binding site volume using SiteMap (90,91) from Schrӧdinger, Inc. Druggability (SiteScore) is calculated 
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based on a weighted sum of the size, enclosure score, and hydrophilic score. A “tight-binding” site 
(submicromolar) would have a predicted SiteScore of 1.0 or greater; a site score of greater than 0.8 is 
thought to distinguish between drug-binding and non-drug-binding sites. Hydrophobicity and 
hydrophilicity scores for an average “tight-binding” site are calibrated to 1.0 in SiteMap.  
A new protein databank (.pdb) file was created every 10 ns for each simulation, starting with the 
first frame post-energy minimization, resulting in 11 .pdb files for each GI.1 and GII.4 proteases for 
analysis. Each .pdb file was imported into Maestro (Schrӧdinger, 2017-1 release) and was prepared using 
the Protein Preparation program. The aforementioned properties were analyzed using SiteMap for each .pdb 
file and an average value was computed for the 11 structures for both GI.1 and GII.4 proteases.   
2.3 Results and Discussion 
2.3.1 Homology modeling of GII.4 norovirus protease 
 No deposited structure currently exists for a GII norovirus protease. Therefore, a homology model 
of the GII.4 norovirus protease was built using the Swiss-Model server (85). PDBID: 3UR6 (1), which 
corresponds to a GI.1 norovirus protease was used as a template structure. The resulting model for the GII.4 
norovirus protease displayed a Global Model Quality Estimation (GMQE) score of 0.78. GMQE scores 
range from 0 to 1.0, with higher scores suggesting a more accurate model. The homology model of the 
GII.4 norovirus protease, along with the crystal structure of a GI.1 norovirus protease (PDBID: 3UR6) were 
then submitted to Molecular Dynamics (MD) simulations for analysis.  
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2.3.2 Backbone flexibility of GI.1 and GII.4 norovirus proteases 
 The root mean square deviation (RMSD) of α-C atoms in the GI.1 and GII.4 norovirus protease 
backbone was calculated over the entirety of each 100 ns simulation. The GI.1 and GII.4 proteases appear 
to show similar flexibility and stability during the 100 ns simulation (Fig. 2.1). The average RMSD for the 
GI.1 protease was 1.54 Å, which was slightly higher than the GII.4 protease (1.45 Å). The trajectories for 
both GI.1 and GII.4 appear to be very similar. The only exception to this observation is around 65 ns, when 
the GII.4 RMSD peaks to 2.4 Å. The peak appears to be created by a transient conformational change in 
the loop comprised of residues Leu122, Thr123, Gly124, Ala/Ser125, Asn126, Ala127, Lys128, 
Gly/Ser129, and Met130. This loop exists away from the substrate binding region such that any transient 
conformational change likely would not have an effect on substrate or ligand binding. Overall, the two 
proteases display similar behavior in terms of flexibility throughout the simulation. 
Figure 2.1. RMSD trajectory of GI.1 norovirus protease (NoVpro, Norwalk strain), and GII.4 
norovirus protease (MVpro, Minerva strain).  Models of GI.1 and GII.4 norovirus proteases were 
submitted to 100 ns molecular dynamics simulations. The RMSD of each model over the course of the 
entire simulation is shown; the inset to the right shows the average RMSD value of GI.1 and GII.4 
norovirus proteases over the 100 ns molecular dynamics simulation. 
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2.3.3 Substrate binding region flexibility and solvent exposure 
 The flexibility and solvent exposure of residues comprising the substrate binding region were 
calculated over the 100 ns simulation for both GI.1 and GII.4 proteases. The residues comprising the 
substrate region (His30, Glu54, Met107, Ile109, Gln110, Arg112, Leu/Thr113, Ser/Met118, Thr134, 
Ile/Thr135, Pro136, Gly137, Asp138, Cys139, His157, Ala/Thr158, Ala159, Ala160, Thr/Ala161, Thr166, 
Val/Ile168), also shown in Figure 2.2, were determined from the structure of a norovirus protease bound 
to a Michael-acceptor peptide inhibitor. The root mean square deviation (RMSD) and root mean square 
GI.1_NoVpro      APPTLWSRVT KFGSGWGFWV SPTVFITTTH VVPTGVKEFF GEPLSSIAIH QAGEFTQFRF 
GII.4_MVpro      APPSIWSRIV NFGSGWGFWV SPSLFITSTH VIPQGAKEFF GVPIKQIQVH KSGEFCRLRF 
                 ***::***:. :********* **::***:** *:* *.**** * *:..* :* ::*** ::** 
  
GI.1_NoVpro      SKKMRPDLTG MVLEEGCPEG TVCSVLIKRD SGELLPLAVR MGAIASMRIQ GRLVHGQSGM 
GII.4_MVpro      PKPIRTDVTG MILEEGAPEG TVVTLLIKRS TGELMPLAAR MGTHATMKIQ GRTVGGQMGM 
                  * :* *:** *:****.*** ** ::****. :***:***.* **: *:*:** ** * ** ** 
  
GI.1_NoVpro      LLTGANAKGM DLGTIPGDCG APYVHKRGND WVVCGVHAAA TKSGNTVVCA VQAGEGETAL E 
GII.4_MVpro      LLTGSNAKSM DLGTTPGDCG CPYIYKRGND YVVIGVHTAA ARGGNTVICA TQGGEGEATL E 
                 ****:***.* **** ***** .**::***** :** ***:** ::.****:** .*.****::* * 
  
Figure 2.2. Sequence alignment and Structure of norovirus protease. Top: Sequence alignment of GI.1 Norovirus 
protease and GII.4 Norovirus protease. The GI.1 and GII.4 norovirus proteases display an overall sequence identity 
of 66.85%. The substrate binding region displays higher conservation (81.8%), as evidenced in the catalytic triad 
(red), S1 substrate binding pocket (cyan), S2 substrate binding pocket (green), and S4 substrate binding pocket 
(magenta). Bottom: Crystal structure of GI.1 Norovirus protease (Norwalk, PDBID: 3UR6). Residues comprising 
the substrate binding are shown in sticks, color scheme as previously described in the sequence alignment.  
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fluctuation (RMSF) were calculated for each residue of the substrate binding site to determine the region’s 
flexibility. The flexibility of the substrate binding region for the GI.1 protease also appears to be very 
similar to the GII.4 protease (Fig. 2.3). The RMSD for the GI.1 protease is 2.12 Å, which again is slightly 
higher than the GII.4 substrate binding RMSD (2.06 Å). The main difference is in residue Gln110, which 
displays an RMSD of 5.3 Å in the GI.1 protease compared to 3.7 Å in the GII.4 protease. Gln110 protrudes 
into the substrate binding region (Fig. 2.2) and has been shown to form hydrogen bonds with norovirus 
protease substrates and ligands. Reduced flexibility of Gln110 in the GII.4 protease could negatively impact 
ligand binding via steric interference. Similar to the RMSD, the RMSF values for the substrate binding 
residues are nearly identical for the GI.1 and GII.4 proteases (0.58 Å and 0.60 Å, respectively). Based on 
Figure 2.3. Per-residue flexibility of the substrate binding region. Top: RMSD of residues 
lining the substrate binding region for GI.1 (black) and GII.4 (red) norovirus proteases. His30, 
Glu54, Met107, Ile109, Gln110, Arg112, Leu/Thr113, Ser/Met118, Thr134, Ile/Thr135, Pro136, 
Gly137, Asp138, Cys139, His157, Ala/Thr158, Ala159, Ala160, Thr/Ala161, Thr166, Val/Ile168, 
are plotted as residues 1-21, respectively; the inset shows the average RMSD for the substrate 
binding region. Bottom: RMSF of residues lining the substrate binding region for GI.1 (black) 
and GII.4 (red) norovirus proteases. Residues are plotted as in top left panel. The inset shows the 
average RMSF for the substrate binding region. 
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these analyses, the overall behavior of the substrate binding residues, in terms of flexibility, appears to very 
similar between the GI.1 and GII.4 proteases. This phenomenon does not come as much surprise, as the 
substrate binding region is highly conserved (81.8% sequence identity).  
 In addition to RMSD and RMSF, the solvent accessible surface area (SASA) for the substrate 
binding region residues was also calculated for both GI.1 and GII.4 proteases (Fig. 2.4). Due to the high 
conservation of this region, the GI.1 and GII.4 proteases display nearly identical SASA values (254.8 Å2 
and 256.3 Å2, respectively). Likewise, the only noticeable differences in SASA between the GI.1 and GII.4 
proteases are the non-conserved residues: Leu/Thr113, Ser/Met118, Ile/Thr135, Ala/Thr158, Thr/Ala161, 
and Val/Ile168. 
2.3.4 Evaluation of the substrate binding region 
 The substrate binding region for both GI.1 and GII.4 proteases were evaluated for druggability, size 
(volume), hydrophobicity and hydrophilicity, as well as a prospective ligand’s propensity for hydrogen 
bond donors or acceptors using Schrodinger’s SiteMap program (Fig. 2.5). Starting with the first frame post 
energy-minimization, a new .pdb file was created corresponding to every 10 ns throughout the 100 ns 
simulations. 
Figure 2.4. Substrate binding region solvent-accessible surface area (SASA). Left: 
SASA of residues lining the substrate binding region for GI.1 (black) and GII.4 (red) 
norovirus proteases. His30, Glu54, Met107, Ile109, Gln110, Arg112, Leu/Thr113, 
Ser/Met118, Thr134, Ile/Thr135, Pro136, Gly137, Asp138, Cys139, His157, Ala/Thr158, 
Ala159, Ala160, Thr/Ala161, Thr166, Val/Ile168, are plotted as residues 1-21, respectively. 
Right: Average SASA of residues lining the substrate binding region. 
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 The sitemap calculations demonstrate that the GI.1 and GII.4 substrate binding regions have similar 
predicted properties. The GII.4 binding site is predicted to be more druggable: the average sitescore is 0.920 
compared to 0.868 for the GI.1 binding site (Fig. 2.5). A SiteScore threshold of 0.8 is used for establishing 
whether a site is likely to be druggable or not (90,91) . Therefore, both GI.1 and GII.4 sites fit the criteria 
but the GII.4 site is predicted to be significantly more druggable (p = 0.045). The two binding sites scored 
nearly the same in regards to hydrophobic character (0.21 for GI.1 vs. 0.22 for GII.4); however, the GII.4 
binding site was predicted to have significantly less hydrophilic character than the GI.1 binding site (0.44 
vs. 0.53, respectively; p = 0.015). Interestingly, for both properties (hydrophobicity and hydrophilicity), the 
two proteases had predicted values far less than the average tight binding site (1.0). One contributing factor 
for this phenomenon could be the use of an apo protease (no ligand) instead of a ligand-bound protease. 
Deposited structures of ligand-bound GI.1 norovirus proteases show well defined binding pockets in 
comparison to the apo form, suggesting that ligand binding may elicit conformational changes within the 
substrate binding region (Fig. 2.6). The lesser defined pockets in the apo proteases could be a reason for 
the low scores in this analysis. Additionally, viral proteases must recognize multiple substrates which are 
Figure 2.5. Substrate binding site predicted properties. Left: Properties including druggability (SiteScore), 
hydrophobicity, hydrophilicity, and the likelihood of a prospective ligand to donate or accept hydrogen bonds (don/acc) of 
the substrate binding region of GI.1 and GII.4 norovirus proteases. The properties were averaged over 11 .pdb files 
corresponding to every 10 ns of the 100 ns simulation. Right: predicted binding site volume for GI.1 and GII.4 norovirus 
proteases. 
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peptidic and large. Therefore, the binding pockets may not be as well defined compared to other proteins 
deemed “tight-binders” by SiteMap which could also contribute to the low scores.  
 The binding sites were also evaluated for their volume as well as the likelihood of a prospective 
ligand to donate or accept hydrogen bonds. Surprisingly, the GII.4 binding site was predicted to be slightly 
smaller than the GI.1 site (158 Å3 vs. 180 Å3) and was predicted to be more likely to accept hydrogen bonds 
compared to the GI.1 site (0.89 vs. 0.69). However, the results were statistically insignificant for both 
volume and hydrogen bond donor/acceptor properties (p = 0.228 and p = 0.083, respectively); the 
statistically insignificant results may have largely been a result of the sample size chosen for the analysis.  
A) 
B) C) 
Figure 2.6. Comparison of apo and ligand bound GI.1 norovirus protease. A) Superposition of apo GI.1 norovirus 
protease (light grey; PDBID: 3UR6(1)) and ligand-bound GI.1 norovirus protease (dark grey; PDBID: 4XBD(4)). The 
substrate binding region residues are colored as in figure 2. Conformational changes elicited by ligand binding are 
highlighted by the red arrows. B) Surface representation of apo GI.1 norovirus protease. C) Surface representation of ligand-
bound GI.1 norovirus protease. With ligand present in the substrate binding region, the binding pockets are more defined than 
in the apo structure, particularly the S2 pocket (yellow outline).  
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2.4 Conclusion 
In conclusion, molecular dynamics (MD) simulations of the GI.1 and GII.4 norovirus proteases 
revealed that, overall, the two proteases have similar properties. Both proteases displayed similar flexibility 
over the entire trajectory; in addition, the substrate binding regions also displayed very similar flexibility 
as well as solvent accessible surface area. The GII.4 substrate binding site is predicted to be more druggable, 
less hydrophilic, potentially more likely to accept hydrogen bonds, and may be smaller in volume in 
comparison to the GI.1 site. Future X-ray crystallographic studies of the GII.4 norovirus protease would 
help to either confirm or contradict the findings presented here. This study demonstrates that GI and GII 
norovirus proteases behave in an overall similar manner. Based on this proposed similarity, a small 
molecule inhibitor developed against a GI or GII norovirus protease would likely have broad-spectrum 
activity against other norovirus genogroups.  
2.5 Author’s Contributions 
 The author, BDK, conducted all of the MD experiments, SiteMap calculations, and data analysis. 
Kendall Muzzarelli helped with data analysis and editing this chapter of the dissertation. 
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CHAPTER 3: EXPRESSION, PURIFICATION, AND 
CHARACTERIZATION OF THE MINERVA VIRUS PROTEASE – A 
NOVEL GII.4 NOROVIRUS PROTEASE 
3.1 Introduction 
Noroviruses, which belong to the Caliciviridae family, are the leading cause of gastroenteritis 
worldwide. Each year in the United States noroviruses are responsible for greater than 20 million cases of 
acute gastroenteritis, leading to an estimated 800 deaths and 71,000 hospitalizations (15). While most cases 
resolve within a week, immunocompromised patients, children, and the elderly have an elevated risk of 
long-term and potentially fatal infections (10-12). Noroviruses are divided into seven genogroups (GI-
GVII); GI is subdivided into genotypes 1-7 and GII is subdivided into genotypes 1-15 (2). Genogroups GI, 
GII, and GIV are infectious in humans (92), with GII and GI predominantly associated with outbreaks 
(9,93). GII.4 viruses are responsible for the majority of human outbreaks, causing an estimated 60-70% of 
such cases (9,94). 
The positive-sense viral RNA is synthesized as a polyprotein, which is cleaved by a 3C-like 
protease (3CLpro). While no anti-norovirus therapy has yet been approved for human use, the 3CLpro, a 
cysteine protease, has emerged as an attractive drug target due its essential role in viral maturation. 
Significant progress has been made targeting norovirus proteases: inhibitors of the 3CLpro have been 
reported with IC50 values in the low nanomolar range (1,4,72,73,75-78,82-84). However, much of this 
progress has been made with GI norovirus proteases, such as the Norwalk virus protease (GI.1) 
(68,71,72,78), Chiba virus protease (64,65), or Southampton virus protease (3,63) serving as the target. To 
date, the MD145 remains the only GII.4 norovirus protease reported in the literature (2).  
We report here for the first time the expression, purification, and characterization of a novel GII.4 
norovirus protease – the Minerva virus protease (MVpro). MVpro was expressed using Escherichia coli 
and purified via 6x-His affinity and size-exclusion chromatography. Pure MVpro was characterized using 
a fluorescence resonance energy transfer (FRET) protease assay. The successful purification and 
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characterization of MVpro increases our knowledge of GII.4 noroviruses and represents a new target to 
guide synthesis of future anti-norovirus therapies.  
3.2 Materials and Methods 
3.2.1 Cloning and small-scale expression 
The DNA fragment encoding the NS6 protease (Genbank accession no: EF684915, which 
corresponds to the 2006b variant of the Minerva virus) was amplified by PCR using the following primers: 
5’-GAATAAGAAGACATAGGTGCCCCACCAAGCATC-3’ (forward); 5’-
GATACGCTCGAGTTATTCAAGTGTAGCTTCC-3’ (reverse). The PCR product was ligated into a 
pSUMO vector containing a T7 promoter and an N-terminal His6-SUMO tag. The resulting clone was 
transformed into Escherichia coli BL21 Codon Plus (DE3) cells for protein expression. 
Small scale (5 mL) cultures were prepared to optimize conditions for protein overexpression. 
Transformed E. coli BL21 Codon Plus (DE3) cells containing the MVpro insert were grown in 5 mL LB 
medium in the presence of streptomycin. Protein expression was induced by addition of isopropyl-β-D-
thiogalactoside (IPTG). Three variables were tested to optimize protein overexpression: 1) OD600 before 
induction, 2) concentration of IPTG, and 3) temperature. Cell cultures were induced at either an OD600 of 
0.5 or 1.0 with the addition of either 0.1 mM, 0.4 mM, 0.6 mM, or 1.0 mM IPTG. After IPTG induction, 
protein expression was conducted at either 37°C for three hours or 15°C overnight. Cells were lysed and 
evaluated by SDS-PAGE (15% w/v polyacrylamide) for protein expression levels and protein solubility. 
3.2.2 Protein expression and purification 
Large scale protein expression was performed using a 2-liter culture. The cultures were grown to 
an OD600 of 1.0 at 37 °C in LB medium.  Protein expression was induced by addition of 0.1 mM IPTG and 
was carried out at 37 °C for 3 hours. The cells were harvested by centrifugation and lysed by French Press.  
The soluble fraction was purified using a Ni2+ affinity column (HisTrap™ HP, GE). To separate the SUMO 
tag from the MVpro, proteolytic cleavage of the His6-SUMO tag with yeast SUMO Protease 1 was 
performed on the eluted fractions. MVpro was then separated from the cleaved His6-SUMO tag by a second 
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round of Ni2+ affinity chromatography. MVpro was further purified by size-exclusion chromatography 
(Superdex 200, GE). The pure MVpro was concentrated to 20 mg/mL in a buffer containing 20 mM Tris-
HCl (pH 8.0), 150 mM NaCl, 5 mM β-mercaptoethanol, and 5% glycerol. Eluted fractions for each step of 
purification were analyzed by SDS-PAGE (15% w/v polyacrylamide) and Coomassie Brilliant Blue 
staining.  
3.2.3 Kinetic enzyme assay 
Purified MVpro was tested for enzymatic activity with a FRET-based enzyme assay. The MVpro 
was diluted in reaction buffer (50 mM HEPES, pH 8.0, 120 mM NaCl, 0.4 mM EDTA, 20% glycerol, and 
4 mM DTT) to a final concentration of 128 nM. Each reaction was initiated by addition of FRET substrate 
(HiLyte Fluor 488 – DFELQGPK(QXL520), purchased from Anaspec, Inc.). The FRET substrate is based 
on the P5-P2’ residues of the Minerva virus NS2/NS3 cleavage site. To determine kinetic parameters, the 
FRET substrate was serially diluted to final concentrations of 100 µM to 49 nM and added to the reaction. 
The final reaction volume was 100 μL. The fluorescence emitted by substrate cleavage was monitored by 
a microplate reader (SpectraMax M5, Molecular Devices, Sunnyvale, CA, USA) at a 488 nm excitation 
wavelength with an emission wavelength of 520 nm. Readings were taken every minute for 20 minutes, 
and the reactions was performed at 37°C. In order to convert RFU into µM, a standard curve was created 
by measuring fluorescence of free HiLyte Fluor 488, which was serially diluted from 250 nM to 3.9 nM. 
All data were plotted and analyzed with GraphPad Prism v. 6.07.   
3.2.4 Inhibition assay with compound A 
Compound A was tested for anti-proteolytic activity against MVpro. Compound A, a white solid, 
is a peptidomimetic protease inhibitor with a molecular mass of 581.4 Da. The compound A structure is 
presented later (Figure 5), and its organic synthesis is described in the Supplementary Information section 
(Figure S3).  
Purified MVpro was diluted to a final concentration of 128 nM in reaction buffer (50 mM HEPES, 
pH 8.0, 120 mM NaCl, 0.4 mM EDTA, 20% glycerol, and 4 mM DTT). Compound A was serially diluted 
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in DMSO and was incubated with diluted enzyme for 90 min at 37°C to ensure complete inactivation. Each 
reaction was initiated by addition of 15 µM FRET substrate (HiLyte Fluor 488 – DFELQGPK(QXL520) , 
purchased from Anaspec, Inc.). The final reaction volume was 100 µL. The fluorescence emitted by 
substrate cleavage was monitored by a microplate reader (SpectraMax M5, Molecular Devices, Sunnyvale, 
CA, USA) at a 488 nm excitation wavelength with an emission wavelength of 520 nm. Readings were taken 
every minute for 20 minutes. The data were plotted and analyzed with GraphPad Prism v. 6.07. The 
Morrison equation for tight-binding inhibitors was used to calculate the Ki.  
3.3 Results and Discussion 
3.3.1 Comparison of GI and GII norovirus proteases 
The genome of noroviruses exists in three open reading frames (ORFs). ORF1, which contains the 
non-structural proteins, is cleaved in five locations by the viral polyprotein (2) (Fig. 3.1A). The Minerva 
virus protease (MVpro) recognizes Q/G (NS2/NS3; NS3/NS4), E/G (NS4/NS5; NS6/NS7), and E/A 
(NS5/NS6) as cleavage junctions (Fig. 3.1A). Comparison of the MVpro cleavage junctions to the Norwalk 
virus protease (NoVpro) cleavage junctions show that the P2-P2’ residues are nearly universally conserved, 
differing only at the P2 residue of the NS4/NS5 junction (Fig. 3.1B). Norwalk virus, the most widely studied 
norovirus, is a GI.1 norovirus and serves as the prototype norovirus. Extending past the P2/P2’ residues 
displays more sequence variability between the GI.1 norovirus (NoVpro) and the GII.4 norovirus (MVpro). 
Overall, the cleavage junctions are well conserved.  
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Additionally, the sequence of MVpro was aligned to the Norwalk virus protease (NoVpro) (68), 
the Southampton virus protease (SVpro) (3), and the Chiba virus protease (CVpro) (67). NoVpro, SVpro, 
and CVpro represent GI.1, GI.2, and GI.4 noroviruses, respectively (95). The alignment in Figure 3.1C 
shows that the GI proteases are highly conserved (at least 90% sequence identity). A higher degree of 
variation exists between genogroups as MVpro is 68.51%, 67.05%, and 66.85% identical to SVpro, CVpro, 
and NoVpro, respectively. Highly conserved areas include the catalytic triad, consisting of His30, Glu54, 
 
 
 
 
 
 
 
 
 
Cleavage Site P4 P3 P2 P1 P1’ P2’ P3’ P4’ 
MVpro NS2/NS3 F E L Q G P E D 
NoVpro NS2/NS3 F H L Q G P E D 
MVpro NS3/NS4 F E L Q G P A L 
NoVpro NS3/NS4 F Q L Q G P T Y 
MVpro NS4/NS5 I K T E G K K G 
NoVpro NS4/NS5 A V P E G K N K 
MVpro NS5/NS6 L S F E A P P S 
NoVpro NS5/NS6 I N F E A P P T 
MVpro NS6/NS7 A T L E G G K S 
NoVpro NS6/NS7 T A L E G G D K 
 
 
GII.4 MVpro   APPSIWSRIV NFGSGWGFWV SPSLFITSTH VIPQGAKEFF GVPIKQIQVH KSGEFCRLRF 
GI.4  CVpro   APPTLWSRVV RFGSGWGFWV SPTVFITTTH VIPTGVREFF GEPIESIAIH RAGEFTQFRF 
GI.1  NoVpro  APPTLWSRVT KFGSGWGFWV SPTVFITTTH VVPTGVKEFF GEPLSSIAIH QAGEFTQFRF 
GI.2  SVpro   APPTLWSRVT KFGSGWGFWV SPTVFITTTH VIPTSAKEFF GEPLTSIAIH RAGEFTLFRF 
              ***::***:. .********* **::***:** *:* ..:*** * *: .* :* ::***  :** 
  
GII.4 MVpro   PKPIRTDVTG MILEEGAPEG TVVTLLIKRS TGELMPLAAR MGTHATMKIQ GRTVGGQMGM 
GI.4  CVpro   SRKVRPDLTG MVLEEGCPEG VVCSILIKRD SGELLPLAVR MGAIASMKIQ GRLVHGQSGM 
GI.1  NoVpro  SKKMRPDLTG MVLEEGCPEG TVCSVLIKRD SGELLPLAVR MGAIASMRIQ GRLVHGQSGM 
GI.2  SVpro   SKKIRPDLTG MILEEGCPEG TVCSVLIKRD SGELLPLAVR MGAIASMRIQ GRLVHGQSGM 
               : :* *:** *:****.*** .* ::****. :***:***.* **: *:*:** ** * ** ** 
  
GII.4 MVpro   LLTGSNAKSM DLGTTPGDCG CPYIYKRGND YVVIGVHTAA ARGGNTVICA TQGGEGEATL E 
GI.4  CVpro   LLTGANAKGM DLGTLPGDCG APYVYKRNND WVVCGVHAAA TKSGNTVVCA VQA------- - 
GI.1  NoVpro  LLTGANAKGM DLGTIPGDCG APYVHKRGND WVVCGVHAAA TKSGNTVVCA VQAGEGETAL E 
GI.2  SVpro   LLTGANAKGM DLGTIPGDCG APYVYKRAND WVVCGVHAAA TKSGNTVVCA VQASEGETTL E 
              ****:***.* **** ***** .**::** ** :** ***:** ::.****:** .*.        
A) 
B) 
C) 
Figure 3.1. Genome organization and alignment to GI noroviruses. A) Norovirus genomes contain three open reading 
frames. Norovirus proteases are responsible for cleavage of the ORF1 polyprotein, which contains the viral non-structural 
proteins. B) Minerva virus protease (GII.4) cleavage site junctions aligned with Norwalk virus protease (GI.1) cleavage site 
junctions. C) Sequence alignment of Minerva virus protease (MVpro), Chiba virus protease (CVpro), Norwalk virus protease 
(NoVpro), and Southampton virus protease (SVpro). MVpro is a GII.4 norovirus whereas CVpro, NoVpro, and SVpro are GI.4, 
GI.1, and GI.2 noroviruses, respectively.  
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and Cys139, the S1 substrate pocket (residues 134-138, and 157), the S2 pocket (residues 30, 109, 112-113, 
and 158-159), the S4 pocket (residues 107, 118, 161, 166, 168), as well as residues which have been 
reported to contribute important hydrogen bonds to the substrate backbone (residues 110, 158, and 160) 
(Fig. 3.1C).  
Due to the high sequence similarity, the structure of MVpro is expected to closely mimic the 
structures of the aforementioned GI norovirus proteases. Additionally, the conserved substrates and 
conserved substrate binding pockets suggest that the shape of the MVpro active site should also closely 
resemble the shape of the NoVpro active site. Therefore, potent inhibitors targeting NoVpro (1,4,72,73,75-
78,82-84) may also be applicable to GII norovirus proteases, such as the MVpro.  
C) 
A) 
D) 
B) 
N
i2
+
 A
ff
in
it
y
 
Cell lysate 
(soluble fraction) 
N
i2
+
 A
ff
in
it
y
 
S
iz
e 
E
x
cl
u
si
o
n
 
ULP-1  
cleavage 
1.  
2.
3. 4.
Figure 3.2. Protein purification scheme. A) Schematic diagram of the purification process for Minerva virus protease. B) 
Uninduced and induced cells as well as cell lysate fractions and the 1st Ni2+ affinity column load, flow-through, and wash. C) 
1st Ni2+ affinity column eluted fractions containing the SUMO-MVpro fusion protein. D) Steps 2 and 3 of scheme A): after 
cleavage with ULP-1, MVpro appears at a MW of ~20 kDa. MVpro is eluted in the flow-through of the 2nd Ni2+ affinity column. 
SE = size exclusion column load. Panels B)-D) are 15% SDS-PAGE gels stained with coomassie blue.  
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3.3.2 Overexpression and purification of Minerva virus protease 
A 2-liter culture of E. coli was used to overexpress MVpro. Prior to the 2-liter culture, 
overexpression conditions were optimized as described in section 2.1. Following optimization and 
expression, the cells were collected by centrifugation and lysed by French press. The soluble fraction of the 
cell lysate was purified according to the scheme shown in Figure 3.2A. The expressed SUMO-MVpro 
fusion protein appears at a molecular weight of ~40 kDa on an SDS-PAGE gel (Fig. 3.2B). After the sample 
was applied to the first HisTrap™ column, a gradient of imidazole was used to elute the SUMO-MVpro 
fusion protein. The fusion protein started to elute at about 174 mM imidazole and reached completion at 
approximately 310 mM imidazole (Figure 3.2C). Before the sample was applied a second time to the 
HisTrap™ column, yeast SUMO protease 1 (ULP-1) was used to cleave the SUMO tag from MVpro (Fig. 
3.2D). Once separated from the SUMO tag, nearly pure MVpro was eluted in the flow-through and wash 
Figure 3.3. Size exclusion chromatography. A) chromatogram 
showing the eluted peak of the size-exclusion column. The 
asymmetrical peak appears to contain two species, dimer (85 mL) 
and monomer (92.5 mL), of MVpro. B) 15% SDS-PAGE gels 
stained with Coomassie Brilliant Blue showing the eluted fractions 
of pure MVpro. Two bands are apparent: ~20 kDa, and ~ 19 kDa 
which suggests auto-proteolysis of the C-terminus.  
A) 
B) 
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of the second HisTrap™ column (Fig. 3.2D). The expected MW of MVpro is 19.3 kDa; MVpro displays 
an apparent MW of ~20 kDa on an SDS-PAGE gel (Fig. 3.2D).  
To ensure pure MVpro was obtained, the sample was further purified with size-exclusion 
chromatography. Figure 3.3A shows a strong peak starting to elute at about 78 mL. Interestingly, instead 
of exhibiting a symmetrical peak, the chromatogram seems to show the presence of two protein species: 
the first species is evidenced by the first peak at 85 mL. A shoulder at 92.5 mL suggests a second protein 
species (Fig. 3.3). The first peak at 85 mL corresponds to a MW of about 36 kDa, or dimer MVpro. The 
shoulder at 92.5 mL corresponds to a MW of about 20 kDa, or monomer MVpro. Based on these data, it 
appears that MVpro, in solution, exists in both monomer and dimer states. The relative strength of the signal 
suggests that the dimer may be slightly favored (Fig. 3.3A).  
Somewhat unexpectedly, the fractions containing MVpro eluted from the size-exclusion column 
appeared to show two distinct bands: one dark band at ~20 kDa and a lighter band just below at ~19 kDa 
(Fig. 3.3B). The presence of any non-specific impurities is unlikely considering the rigorous purification. 
Inspection of the MVpro sequence revealed a Q/G, E/G, and an E/A cleavage junction at the C-terminus. 
Figure 3.4. Purified inactive MVpro. Inactive MVpro was 
created using Phusion High-Fidelity PCR kit to mutate the 
catalytic cysteine to alanine (C139A) using the following 
primers: forward 5’ P-ACA CCA GGT GAT GCA GGC TGT 
CCC TAC 3’; reverse 5’ P-GG TGC CTA GAT CCA TGC 
TTT TGG CGT TGG 3’. Inactive (C139A) MVpro was 
purified in the same manner as active MVpro as described in 
sections 2.1, 2.2, and 3.2. Elution fractions from size-
exclusion chromatography show that the C139A mutation 
prevents formation of the second band at ~19 kDa on an SDS-
PAGE gel. 
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Mutating the catalytic cysteine to an alanine (C139A) prevented the two bands from appearing on an SDS-
PAGE gel suggesting that the faint band at ~19 kDa may be the result of auto-proteolysis at the C-terminal 
end of the protein (Fig. 3.4).  
3.3.3 Characterization of enzymatic activity 
Following successful purification, MVpro was subjected to a FRET based assay to test for 
enzymatic activity. A protocol described by Kyeong-Ok Chang’s group was used to design the assay to 
detect MVpro activity (2).  
The substrate used for our assay was HiLyte Fluor 488 - DFELQGPK(QXL520) - NH2, (purchased 
from Anaspec, Inc). This substrate represents the P5-P2’ residues of the MVpro NS2/NS3 cleavage site. A 
C-terminal lysine was added in order to attach the QXL520 flourescence quencher to the substrate. MVpro 
efficiently cleaves the HiLyte Fluor 488 - DFELQGPK(QXL520) - NH2 substrate as evidenced by the 
kinetic data, in which the initial velocity is plotted as a function of substrate concentration (Fig. 3.5).  
Compared to other norovirus proteases, MVpro appears to be more efficient than both NoVpro 
(GI.1) and MD145pro (GII.4) (2). The enzymatic data for these proteases are shown in Table 1. MVpro is 
nearly twice as efficient as NoVpro and slightly more efficient than MD145pro: the specificity constants 
(kcat/KM) for MVpro, NoVpro, and MD145 are 2.024 x 103 (M-1min-1), 1.111 x 103 (M-1min-1), and 1.873 x 
Figure 3.5. Enzyme kinetics of MVpro. Cleavage velocity 
of NS2/NS3 substrate (HiLyte Fluor 488 - 
DFELQGPK(QXL520) - NH2) plotted as a function of 
substrate concentration. MVpro exhibits classic Michaelis-
Menten kinetics. Data is represented as mean velocity ± 
standard error of the mean (SEM). 
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103 (M-1min-1), respectively (Table 1). Although the specificity constants of the three proteases are similar, 
the turnover (kcat) and Michaelis constant (KM) are drastically different. MVpro cleaves the NS2/NS3 
substrate at rate 15-fold slower when compared to MD145pro and 18-fold slower when compared to 
NoVpro. However, MVpro displays a 23-fold increase in affinity for the NS2/NS3 substrate compared to 
MD145pro and a 39-fold increase compared to NoVpro (Table 1) . 
Differences in experimental set up may account for the variation seen in the enzymatic data (Table 
1).  First, the substrate presented here used HiLyte Fluor 488/QXL520 as the fluorogenic pair for the 
NS2/NS3 substrate compared to the edans/dabcyl pair used by Chang et al. (2). It is likely that the different 
fluorescent pairs would have an effect on substrate binding. Second, the assay presented here is likely more 
sensitive in the nanomolar range. The MVpro NS2/NS3 substrate was serially diluted from concentrations 
ranging from 100 µM to 98 nM, compared to the NoVpro substrate which was serially diluted from ~640 
µM to ~40 µM (2).  
 
Table 3.1. Kinetic parameters for MVpro, NoVpro, and MD145. *MVpro data is represented as the mean ± standard 
error. Experiments were performed in triplicate. 
#
Data extracted from Chang et al. 2012(2). 
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3.3.4 Inhibition of the Minerva virus protease by compound A 
Based on the high affinity of MVpro for the NS2/NS3 substrate, a peptidomimetic inhibitor 
resembling the substrate was synthesized. Compound A is a tetrapeptide inhibitor containing a hydrophobic 
cap and an aldehyde warhead (Fig. 3.6). Compound A potently inhibits MVpro, exhibiting an IC50 of 112 
± 25 nM and a Ki of 49.7 ± 2.3 nM (Fig. 3.6).  
Previous studies have indicated that inhibitors containing an aldehyde warhead may interact 
covalently with the catalytic Cys139 of norovirus proteases (4,72,73,78,83). Compound A was therefore 
expected to inhibit MVpro covalently. Time course assays performed with compound A show that full 
inactivation of MVpro by compound A is achieved after 90 minutes incubation at 37°C (Fig. 3.7). A zero-
minute incubation resulted in an IC50 value of ~700 nM, compared to the 112 nM activity after 90 minutes 
incubation (Fig. 3.7). This suggests that compound A may inhibit MVpro covalently. It is possible that the 
IC50 at zero minutes incubation is representative of a non-covalent collision complex, whereas the 90-minute 
IC50  may represent full, covalent inhibition. To date, limited data showing inhibition of GII.4 norovirus 
proteases exists (1,2,83). Compound A, therefore, represents an advanced starting point for the design of 
against GII norovirus protease inhibitors.  
Compound A 
IC50 (nM) Ki (nM) 
112 ± 25 49.7 ± 2.3 
 
Figure 3.6. Inhibition of MVpro by 
compound A. Structure of and inhibition data 
for compound A. The data is represented as the 
mean ± one standard deviation. The 
experiment was performed in duplicate.  
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3.4 Conclusion 
We report here for the first time successful expression, purification, characterization, and inhibition 
of the Minerva virus protease (MVpro), a GII.4 norovirus protease. Pure MVpro, which appears to exist as 
both monomer and dimer in solution, cleaves the NS2/NS3 substrate more efficiently than other norovirus 
proteases such as the Norwalk virus protease (GI.1) and the MD145 protease (GII.4). Inhibition studies 
involving GII.4 norovirus proteases remain underrepresented in the literature, despite GII.4 noroviruses 
being responsible for a majority of outbreaks. Compound A, a potent inhibitor of MVpro, may be a good 
starting point for the design of inhibitors to target GII norovirus proteases. Furthermore, the results 
presented here will allow for future characterization of MVpro inhibitors as they are synthesized.  
3.5 Author’s Contributions  
 The author, BDK, conducted the protein expression and purification experiments. The author also 
characterized the enzymatic activity of the purified enzyme and characterized the inhibitory activity of 
compound A. Joshua Holcomb assisted with protein expression and purification. Compound A was 
synthesized in the Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University 
School of Medicine, Atlanta, GA, by Dr. Peng Liu and Dr. Shaoman Zhou under the direction of Dr. Franck 
Amblard and Dr. Raymond Schinazi.  
  
Figure 3.7. Compound A activity over time. The IC50 
for compound A was plotted as a function of incubation 
time (37°C). 90 minutes are required for complete 
inactivation of MVpro by compound A.  
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CHAPTER 4: INCREASED POTENCY OF ALDEHYDE VERSUS 
MICHAEL ACCEPTOR BASED PEPTIDOMIMETICS: A STRUCTURAL 
COMPARISON OF NOROVIRUS GII PROTEASE INHIBITORS 
4.1 Introduction 
In the United States noroviruses are responsible for 19-20 million annual cases of acute 
gastroenteritis. These outbreaks lead to roughly 800 deaths and 71,000 hospitalizations per year with a total 
cost of ~2 billion US dollars(14,15). While healthy individuals usually experience symptoms for 48 hours 
or less, children and elderly patients are at higher risk for developing long-term or even fatal infections(10-
12) predominantly associated with norovirus genogroups GI and GII.   
During viral maturation, the 3C-like protease (3CLpro) cleaves the polyprotein providing an 
attractive drug target for pharmacologic therapy. Recent advances facilitated by the discovery of the 
3CLpro(63) and subsequent elucidation of its crystal structure(67,68), development of a FRET-based 
assay(2) and  replicon system(71) have allowed for structure-based design and evaluation of 3CLpro 
inhibitors. To date, nearly all experimental norovirus protease inhibitors are peptidomimetic and covalent 
containing an aldehyde(1,4,72,73) or bisulfite-adduct salt warhead(1,75) ; the latter is thought to serve as a 
pro-drug to the aldehyde form. Additional warheads that have been reported include α-ketoamide(1,76), α-
ketoheterocycle(76), or α-hydroxyphosphonate(77) warheads as well as an active site directed peptide 
inhibitor with a propenyl-ethyl-ester extension acting as a Michael acceptor warhead(3).  
Previous studies suggest that inhibitors with an aldehyde warhead targeting the catalytic cysteine 
of the norovirus protease are more potent compared to other warheads(1,4,72,73,75-78). However, a softer 
electrophiles, such as a Michael acceptor, may be a more attractive warhead to react with thiol groups 
compared to aldehydes in order to minimize potential risk of off-target effects (96).  In this report, we tested 
two novel inhibitors and two commercially available protease inhibitors (chymostatin, a chymotrypsin and 
papain inhibitor(97,98), and rupintrivir, a rhinovirus and enterovirus protease inhibitor(99,100)) against the 
Minerva virus 3C-like protease (MVpro) – a GII norovirus which may be more clinically relevant than GI 
noroviruses like the Norwalk virus (8,9). A detailed structural analysis comparing the activity of aldehyde 
 30  
 
 
 
kinetic FRET-based assay, automated covalent docking, and molecular dynamics (MD) simulations. 
4.2 Materials and Methods 
4.2.1 Protein expression and purification 
The DNA fragment encoding the NS6 protease from the Minerva virus (Genbank accession no: 
EF684915, which corresponds to the 2006b variant of the Minerva virus) was amplified by polymerase 
chain reaction (PCR): Forward primer: 5’ GAA TAA GAA GAC AT AGGT GCC CCA CCA AGC ATC 
3’; reverse primer: 5’ GAT ACG CTC GAG TTA TTC AAG TGT AGC TTC C 3’. 
The resulting PCR product was cloned into a pSUMO vector containing an N-terminal His6-SUMO 
tag. The resulting clone was transformed into Escherichia coli BL21 Codon Plus (DE3) cells for protein 
expression. The transformed clones were grown to an OD600 (optical density at 600 nm) of 1.0 at 37 °C in 
LB medium.  Protein expression was induced by addition of 0.1 mM isopropylthio-β-D-galactoside (IPTG) 
and was carried out at 37 °C for 3 hours. The cells were harvested by centrifugation and lysed by French 
Press.  The soluble fraction was purified using a Ni2+ affinity column (HisTrap™ HP, GE). Proteolytic 
cleavage of the His6-SUMO tag with yeast SUMO Protease 1 was performed on the eluted fractions. 
MVpro was separated from the cleaved His6-SUMO tag by a second round of Ni2+ affinity chromatography 
and further purified by size-exclusion chromatography (Superdex 200, GE). Pure MVpro was concentrated 
to ~20 mg/mL in a buffer containing 20 mM Tris-HCl (pH 8.0), 150 mM NaCl, 5 mM β-mercaptoethanol, 
and 5% glycerol. 
4.2.2 Kinetic IC50 assay 
Inhibitor potency was evaluated using a FRET-based fluorometric enzyme assay. Purified MVpro 
was diluted in reaction buffer (50 mM HEPES, pH 8.0, 120 mM NaCl, 0.4 mM EDTA, 20% glycerol, and 
4 mM DTT) to a final concentration of 128 nM. Inhibitors were serially diluted and incubated with the 
enzyme at 37°C for 90 minutes. Novel inhibitors, compounds A and B, were synthesized at Emory 
University School of Medicine. Commercially available protease inhibitors, chymostatin, a chymotrypsin 
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and papain inhibitor(97,98)  and rupintrivir, a rhinovirus and enterovirus protease inhibitor(99,100), which 
has also shown to have anti-norovirus activity (101), were purchased from Calbiochem and Axon 
MedChem, respectively. Each reaction was initiated by addition of the FRET substrate at a final 
concentration of 15 μM. The FRET substrate (HiLyte Fluor 488 – DFELQGPK(QXL520), purchased from 
Anaspec, Inc.), is based on the P5-P2’ residues of the Minerva virus NS2/NS3 cleavage site. The final 
reaction volume was 100 μL. The fluorescence emitted by substrate cleavage was monitored by a microplate 
reader (SpectraMax M5, Molecular Devices, Sunnyvale, CA, USA) at a 488 nm excitation wavelength with 
an emission wavelength of 520 nm. Readings were taken every minute for 20 minutes. The FRET data were 
plotted with GraphPad Prism to determine the IC50 values. IC50 values are representative of the mean ± 
standard error of the mean (SEM) of at least duplicate trials.   
4.2.3 Covalent docking and molecular dynamics simulations 
Prior to covalent docking and MD simulations, a homology model of the MVpro was created using 
the SwissModel(85) server, with 2IPH.pdb serving as the template (an existing crystal structure of the 
Southampton virus protease bound to a peptidyl inhibitor(3)). Automated covalent docking was performed 
with CovDock(102,103) (Schrödinger, Inc.). Inhibitors were then docked against 2IPH.pdb. Sequence 
comparison was also carried out between GI (e.g. Southampton virus) and GII noroviruses (e.g. Minerva 
virus) (Fig. 4.1).  
Coordinates from the covalent docking output were then used to manually place the inhibitors into 
the active site of the MVpro homology model. The docked complexes were then prepared for MD 
simulations. System preparation was carried out in VMD(86), utilizing the docked MVpro-inhibitor 
Figure 4.1. Sequence alignment and homology modeling results. The sequence alignment for the homology modeling is 
shown. The GII.4 norovirus protease (shown as Model_01: A/B) was aligned to a GI norovirus protease (PDBID: 2IPH (3) to 
be used as a template structure. Areas with warm colors (orange) represent low quality predictions; areas with cool colors 
(blue) show high quality prediction. The resulting model displayed a Global Model Quality Estimation (GMQE) score of 
0.86. 
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complexes as the starting coordinates. The MVpro–inhibitor complexes were placed in a TIP3P water box 
and were neutralized by adding magnesium chloride. Constraints for the entire simulation were placed on 
the sulfur atom of the catalytic Cys139 as well as the reactive carbon atom on the inhibitor to simulate a 
covalent bond. Molecular dynamics simulations were performed with NAMD(89) v 2.9 for 40 ns as 
previously described(87,88,104). The last 10 ns of each trajectory were analyzed with VMD. Hydrogen 
bonds were identified with a 3.0 Å and a 20° cut-off.  
4.3 Results 
4.3.1 Predicted Structure of MVpro  
A homology model of the MVpro structure was built using the SwissDock server (Fig. 4.1). The 
Southampton virus protease (SVpro), a GI.1 norovirus protease, was used as a template to build the MVpro 
model. Sequence alignment showed MVpro and SVpro share 68.51% sequence identity. The resulting 
model displayed a Global Model Quality Estimation (GMQE) score of 0.86. The GMQE scoring function 
is expressed as a number between 0 and 1, with higher numbers indicating higher reliability of the model 
(85).  
The predicted MVpro structure is shown in Figure 4.2A. Similar to other norovirus proteases, 
MVpro adopts a chymotrypsin-like fold and consists of an N-terminal twisted β-sheet domain and a C-
terminal β-barrel domain. The position of the catalytic triad is highly conserved as well; His30, Glu54, and 
Cys139 reside in the cleft between the two domains. Figure 4.2B illustrates a surface representation with 
the predicted substrate binding region and substrate binding pockets annotated. The substrate binding 
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pockets are shown as follows: S1 consisting of residues 134-138 and 157, S2 consisting of residues 30, 109, 
112, 113, 158, and 159, and S4 consisting of residues 107, 118, 161, 166 and 168. The predicted binding 
sites are based on previously published interactions between a peptide-inhibitor and the SVpro (3).  
4.3.2 Aldehyde Inhibitors demonstrate greater potency than ,  unsaturated ethyl ester Michael 
acceptor inhibitors 
Novel inhibitors (Table 4.1) incorporating either an aldehyde warhead (compound A) or a Michael 
acceptor warhead (compound B) were synthesized and tested for their activity against MVpro. Unpublished 
results in our lab suggest that the P3 residue of norovirus protease inhibitors may form hydrogen bonds 
with protease backbone atoms within one of the substrate binding pockets; therefore, a tyrosine was 
incorporated at the P3 position to replace the purely hydrophobic group. Compound A and compound B 
consist of a P1 glutamine surrogate, a leucine in the P2 position, a tyrosine in the P3 position, and an N-
terminal benzyloxycarbonyl (Cbz) cap, thereby mimicking the natural P4-P1 cleavage site residues (Table 
Glu54 
His30 
Cys139 
A) 
S1 Pocket 
Catalytic 
Triad 
S4 Pocket 
Ala160 
S2 Pocket 
Oxyanion 
Hole 
B) 
Figure 4.2. Predicted structure of the Minerva virus protease. A) Homology model of the Minerva virus protease 
(MVpro) built with the SwissDock server using the Southampton virus protease (PDBID: 2IPH) as a template. The model is 
represented as a rainbow cartoon where the N-terminus is blue and the C-terminus is red. The model has a predicted Global 
Model Quality Estimation (GMQE) score of 0.86. B) Surface representation of the MVpro homology model. The showing 
substrate binding channel represented by a dash line; the S1 substrate binding pocket is colored cyan (residues 134-138, and 
157), the S2 pocket (residues 30, 109, 112, 113, 158, and 159) is colored green, the S4 pocket (residues 107, 118, 161, 166, 
and 168) is colored magenta, the catalytic triad is colored red, Ala160 is colored orange, and the oxyanion hole is colored 
blue. 
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4.1). Commercially available protease inhibitors chymostatin (Calbiochem) containing an aldehyde 
warhead and rupintrivir (Axon MedChem) containing a Michael acceptor moiety were purchased and used 
as nonspecific controls. Chymostatin and rupintrivir follow a P4-P1 structure similar  
to that of compound A and compound B.  
The four inhibitors were subjected to a kinetic FRET based assay as described in section 2.2. 
Inhibitors against MVpro containing an aldehyde warhead outperformed those containing a Michael 
acceptor warhead (Table 4.1). Compound A was the most potent inhibitor, displaying an IC50 value of 
0.134 ± 0.003 µM. Chymostatin and rupintrivir were about 10-fold and 100-fold less potent than compound 
A with IC50 values of 1.51 ± 0.04 µM and 19 ± 1.3 µM, respectively, while compound B showed no 
inhibitory activity against MVpro (>50 µM) (Table 4.1).  
Table 4.1. Chemical structures and IC
50
 values of Compound A, Compound B, chymostatin, and rupintrivir. Compound 
A and chymostatin contain an aldehyde warhead, whereas compound B and rupintrivir contain a Michael acceptor moiety as a 
warhead. 128 nM MVpro was incubated with each respective inhibitor for 90 minutes at 37°C before addition of the FRET 
substrate. IC
50
 values are representative of the mean ± SEM of at least duplicate trials for each inhibitor.    
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4.3.3 Predicted Binding pose examination 
The program CovDock (102) (Schrödinger, Inc.) was used to examine the predicted binding pose 
of these inhibitors to MVpro. A striking difference in the predicted binding poses is evident between 
inhibitors with an aldehyde warhead and those with Michael acceptor warheads. The carbonyl oxygen from 
P1 
P2 
Cap 
Warhead 
P3 
P1 
P2 
Cap 
Warhead 
P3 
P1 
P2 
Cap 
Warhead 
P3 
P1 
P2 
Cap 
Warhead 
P3 
S1 
Pocket 
S4 
Pocket 
S2 
Pocke
S1 
Pocket
S4 
Pocket
S2 
Pocke
S1 
Pocket
S4 
Pocket
S2 
Pocke
S1 
Pocket
S4 
Pocket
S2 
Pocke
D) C) 
B) A) 
Figure 4.3. Pose examination after automated covalent docking. Output pose from covalent docking with Minerva 
protease. MVpro is shown as a colored surface and the inhibitors are shown as sticks. A) compound A B) chymostatin C) 
compound B D) rupintrivir. The color scheme for the protease is the same as described in figure 1B. Compound moieties are 
labeled with white text; protein binding pockets are labeled with black text. The P1, P2, P3 and cap groups of aldehyde-
containing inhibitors compound A and chymostatin interact properly with their respective pockets (S1, S2, S4). Michael 
acceptor containing inhibitors compound B and rupintrivir, however, display a pose where the warhead displaces the P1 and 
P2 groups out of their normal binding pockets.  
compound A chymostatin 
compound B rupintrivir 
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the aldehyde warheads of both compound A and chymostatin is facing the oxyanion hole formed by residues 
Gly137 and Cys139 (Fig. 4.3). The position of the aldehydes for compound A and chymostatin are similar 
to that observed for the scissile carbonyl of the natural substrates for the NoVpro(78).  Additionally, the P1 
glutamine surrogate of compound A is positioned properly in the S1 pocket allowing hydrogen bond 
formation with Thr134 – a conserved substrate-protease interaction in the S1 pocket(78) (Fig. 4.4). 
Gln110 
Arg162 
Thr158 Ala160 
Thr134 
Ala160 
Thr158 
His157 Ala160 
Thr134 
Gln110 
Cys139 
A) B) 
C) D) 
Figure 4.4. Backbone hydrogen bonding. Output poses from covalent docking are zoomed-in, showing hydrogen bonding 
between the backbone of inhibitors and residues of the substrate binding pockets. Gln110, Thr158, and Ala160 are important 
residues for contributing to hydrogen bonds. Binding poses of A) compound A, B) chymostatin, C) compound B, and D) 
rupintrivir. The backbone atoms of compound A and chymostatin, which both contain an aldehyde warhead, each participate 
in four hydrogen bonds with surrounding residues. The backbone atoms of compound B and rupintrivir, which contain 
Michael acceptor warheads, display one and zero backbone hydrogen bonds, respectively. 
compound A chymostatin 
compound B rupintrivir 
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Although the P1 moiety of chymostatin faces towards the S1 pocket, due to its size and hydrophobicity it 
does not participate in the same interactions as the glutamine surrogate present in compound A.  
Furthermore, compound A and chymostatin are properly positioned so that their P2 residues occupy 
the S2 subsite. Importantly, the respective positions of compound A and chymostatin facilitate hydrogen 
bonding between the backbone atoms of the inhibitors and the sidechain of Gln110, as well as protein 
backbone atoms from Thr158 and Ala160 (Fig. 4.4). Hydrogen bonding with residues 158 and 160 have 
also been shown to be important in substrate recognition by NoVpro(78). 
Alternatively, the Michael acceptor warheads in compound B and rupintrivir do not occupy the 
oxyanion hole (Fig. 4.3) but rather are extended towards and fill the S2 pocket. As a result, their P1 
glutamine surrogates face the other side of the dII loop(78)(Fig. 4.3) towards His30 and Ser14 instead of 
interacting with Thr134 and His157 of the S1 binding pocket.  In addition, the hydrophobic P2 sidechains 
for compound B and rupintrivir occupy the S1 pocket (Fig. 4.3) resulting in no hydrogen bonding 
interactions with the backbone atoms of Thr134, or Thr158; rupintrivir also did not form a hydrogen bond 
with Ala160 (Fig. 4.4). 
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4.3.4 Assessment of hydrogen bonding with MD simulations 
To further assess the differences in hydrogen bonding between the two classes of inhibitors, the 
inhibitor–MVpro complex structures were each subjected to 40 ns MD simulations and the hydrogen 
bonding networks of each complex were evaluated over the last 10 ns of each simulation.  As expected, 
aldehyde containing inhibitors, compound A and chymostatin, formed the most hydrogen bonds with an 
average of 2.27 and 0.92 hydrogen bonds per frame, respectively (1 frame = 2 fs) (Fig. 4.5). Compound A 
was found to most commonly form hydrogen bonds with side chain atoms from residues Thr134 and His157 
(S1 pocket), the amide nitrogen of residue Gly137 (oxyanion hole), and backbone atoms from residues 
Thr158 and Ala160. The hydrogen bonding network with the backbone atoms Thr158 and Ala160 suggests 
compound A adopts an extended β-strand conformation, similar to that seen when the substrate binds to 
NoVpro(78). Chymostatin also exhibits hydrogen bonding with Ala160, but also forms unique hydrogen 
bonds with side chains of residues Arg162 and Gln110.  
In contrast, compound B and rupintrivir displayed an average of 0.76 and 0.22 hydrogen bonds per 
frame, respectively (Fig. 4.5). Compound B unexpectedly hydrogen bonded with Ala160 and Gly137 which 
Figure 4.5. Hydrogen bonding analysis. The number of hydrogen bonds between each inhibitor  and MVpro over the last 
10 ns of the 40 ns simulation measured each timestep (2 fs). The average number of hydrogen bonds per frame ± SEM for 
each inhibitor are shown in the inset on the right: compound A = 2.27 hydrogen bonds/timestep; compound B =  0.76 
hydrogen bonds/timestep;  chymostatin = 0.92 hydrogen bonds/timestep; rupintrivir = 0.22 hydrogen bonds/timestep.  
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was similar to that seen for compound A. Additionally, compound B formed hydrogen bonds with Gln110, 
similar to chymostatin, as well as the unique yet infrequent formation of hydrogen bonds with Ser28. 
Rupintrivir also formed hydrogen bonds with Gly137 and Gln110, but less frequently than the other 
inhibitors; a unique hydrogen bond with His30 was formed in rare cases.  
4.4 Discussion 
Previous studies have suggested that norovirus 3C-like proteases (3CLpro), such as the Norovirus 
GI.1 (Norwalk virus) protease, are more susceptible to inhibition via an aldehyde-containing inhibitor 
compared to inhibitors containing α-ketoamides, α-ketoheterocycles, or Michael acceptors(1,4,72,73,75-
78). Here we suggest that aldehydes are better warheads to inhibit Norovirus GII.4 (Minerva virus) protease 
than ,  unsaturated ethyl ester Michael acceptors. Compound A and chymostatin (aldehyde warheads) 
are nearly 140-fold and 13-fold more potent than rupintrivir (Michael acceptor warhead), respectively.  
The inhibitors containing aldehyde warheads are positioned for optimal interactions with the 
protease. The carbonyl oxygen for each aldehyde inhibitor (compound A and chymostatin) occupies or 
faces towards the oxyanion hole in the predicted binding pose (Fig. 4.3). Furthermore, the P1 and P2 side 
chains are optimally positioned to interact with their respective binding pockets. The backbone atoms of 
these inhibitors are positioned for hydrogen bond formation with backbone atoms of Thr158 and Ala160, 
which have been shown to be important residues involved in substrate recognition(78). Compound A and 
chymostatin also form the most hydrogen bonds per frame during the molecular dynamics simulations (Fig. 
4.5).  
Although hydrogen bonds may not be directly correlated with inhibitor potency, the aldehyde-
containing inhibitors may be more efficiently recognized by the protease, and may display higher specificity 
for norovirus 3CLpro due to the hydrogen bonds that are formed. Furthermore, the carbonyl oxygen atom 
in both compound A and chymostatin is predicted to be positioned in or near the oxyanion hole, potentially 
stabilizing any charged transition-state intermediates during covalent attachment to the catalytic Cys139.  
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For this analysis, we were unable to detect the IC50 value of compound B with our assay (>50 µM) 
even though the hydrogen bonding network of compound B resembled the networks of compound A and 
chymostatin more than it resembled the network of rupintrivir. During the MD simulation, compound B 
forms hydrogen bonds with Ala160 and Gly137, suggesting that the P1 glutamine surrogate may briefly fill 
the S1 pocket during the simulation. Therefore, one would expect compound B to be more efficiently 
recognized by the enzyme and possibly more potent than rupintrivir. The kinetic enzyme assay clearly 
shows a result contrary to this prediction. Additional studies, including co-crystallization of the MVpro 
structures with each inhibitor, will need to be performed to further understand the results presented here.  
4.5 Conclusion 
This study provides data supporting the assertion that inhibitors with an aldehyde warhead 
(compound A and chymostatin) are more potent against a Norovirus GII 3C-like protease (Minerva virus) 
than inhibitors with an ,  unsaturated ethyl ester Michael acceptor moiety (compound B and rupintrivir). 
It appears that aldehyde warheads allow for an inhibitor conformation that facilitates proper P1 and P2 
hydrogen bonding interactions with the protease as well as occupation of the oxyanion hole. Alternatively, 
the ,  unsaturated ethyl ester Michael acceptor warhead appears to disrupt these important interactions. 
Therefore, we propose that aldehydes may have a distinct advantage over Michael acceptors for two 
reasons: first, increased recognition by the enzyme due to optimized hydrogen bonding and P1 and P2 
interactions, and second, by oxyanion hole mediated stabilization of intermediate species during the 
reaction. Future studies, including co-crystallization of the MVpro structures with each inhibitor as well as 
exploration of different classes of covalent warheads, will help us to better understand the results presented 
here. 
4.6 Author’s Contributions  
The author, BDK, conducted the protein expression and purification experiments, the covalent 
docking experiments, the molecular dynamics experiments, and the kinetic IC50 assays. Joshua Holcomb 
assisted with protein expression and purification. Compound A and B were synthesized in the Laboratory 
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of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, 
GA, by Dr. Peng Liu and Dr. Shaoman Zhou under the direction of Dr. Franck Amblard and Dr. Raymond 
Schinazi. 
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CHAPTER 5: FUTURE DIRECTION - NOROVIRUS 
 The norovirus project in the Kovari lab has, to date, designed and tested nearly 40 protease 
inhibitors against GI.1 and GII.4 norovirus protease in the biochemical enzyme assay. For intellectual 
property reasons the data is not shown. Three lead compounds are progressing in to animal trials to evaluate 
pharmacokinetic and in vivo anti-norovirus activity. Future goals of the norovirus project include the design, 
evaluation, and development of inhibitors with more potency against norovirus proteases as well as 
enhanced cell permeability. The long-term goal of the norovirus project is to advance into human clinical 
trials. 
 In addition, an X-ray crystal structure of the GII.4 norovirus protease (Minerva), would provide 
valuable information for future drug design. Computational studies in our lab have suggested that the GII 
norovirus protease binding site may be slightly smaller than the GI norovirus protease binding site. An X-
ray crystal structure of the GII.4 protease would confirm or reject this hypothesis.  
 Finally, the mechanism of the three lead compounds remains inconclusive. Biochemical assays 
performed in our lab, including the timecourse assay described in chapter 3, as well as kinetic data suggest 
that the compounds inhibit the norovirus protease with a covalent bond. However, LC-MS/MS experiments 
did not show evidence of a drug-protease adduct; the covalent bond may be reversible. Future experiments, 
including X-ray crystallography (co-crystallization with the compound), would help test this hypothesis.  
 Experiments to be performed: 
 Incubate 100 μM high affinity compound with 10 μM NV protease for at least 90 minutes in 
reaction buffer, followed LC-MS/MS to determine covalent bond. 
 Crystallization of apo NV GII.4 protease 
 Co-crystallization of NV GII.4 and/or NV GI.1 protease with a high affinity compound. 
 Inhibit NV GII.4 or NV GI.1 with high affinity compound, followed by dialysis or gel filtration 
chromatography. Measure dialyzed or gel filtered enzyme for enzymatic activity. If the enzyme 
remains inhibited, the compound may be acting via a covalent bond. If the enzyme displays activity 
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after dialysis or chromatography, the compound may not have been covalently attached to the 
enzyme. 
 Conformational analysis of aldehyde inhibitor in comparison to Michael-acceptor inhibitor (see 
chapter 4) using computational methods such as SYBIL. Low energy conformation of Michael-
acceptor warhead may not allow covalent attachment to Cys139. 
 Pharmacophore and 3-D QSAR modeling for NV protease inhibitors. 
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SECTION II: BIOCHEMICAL, STRUCTURAL, AND DRUG DESIGN 
STUDIES OF ZIKA VIRUS PROTEASE 
CHAPTER 6: ZIKA VIRUS INTRODUCTION 
6.1 Zika Virus classification and epidemiology 
Zika virus (ZIKV) is a single-stranded, positive-sense RNA virus belonging to the flaviviradae 
family. Zika virus is spread by the Aedes spp. mosquitoes and is closely related to other mosquito-borne 
flaviviruses such as West Nile (WNV), dengue (DENV), Japanase encephalitis (JEV), and yellow fever 
(YFV) (105,106).  
ZIKV was first discovered in Uganda in 1947 and has diverged into two distinct lineages: African 
and Asian (107). Since its discovery, ZIKV has spread to Yap Island in 2007, French Polynesia in 2013-
2014, and the Americas in 2015-2016. The most recent outbreak in the Americas is associated with the 
Asian lineage (108,109). As of November 2016, a total of 171,553 confirmed cases were reported in 48 
countries and territories in the Americas (106). The number of suspected cases associated with the current 
outbreak may be upwards of 1 million (110). In addition to being spread by mosquitos, ZIKV can be 
transmitted from an infected mother to fetus, via sexual transmission, potential transmission through 
breastfeeding, blood transfusions, and direct transmission(106).  
ZIKV was previously thought to be a fairly mild infection, with most adults experience mild 
symptoms such as rash, fever, arthralgia, and conjunctivitis (111,112).  However, the most recent outbreak 
is associated with more severe complications such as Guillain-Barré syndrome, meningoencephalitis, acute 
myelitis, and microcephaly (106,113,114). In vitro and in vivo experiments have shown ZIKV causing 
damage in neural tissue (115-118). In the United States, 10% pregnancies with laboratory-confirmed Zika 
virus infection resulted in birth defects (119). In pregnancies with confirmed Zika virus infection in the first 
trimester, the birth defect rate increases to 15% (119).    
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6.2 Zika Virus tropism 
In vitro studies have shown that ZIKV can replicate in placental macrophages, trophoblasts, fetal 
endothelial cells (120,121), human uterine fibroblasts (122). ZIKV RNA has been detected in developing 
brain, cord blood, amniotic fluid, and placenta tissue of human fetuses (123,124). In adults, ZIKV has been 
detected in several bodily fluids (semen, saliva, tears, urine), immune privileged sites such as the eyes, 
brain, and testes, and the female genital tract (124). Specifically, ZIKV RNA has been found in human 
conjunctival fluid (125), human cervical fluid (126), and has been shown to persist in vaginal secretions for 
more than 11 weeks (127), and semen for up to 6 months (128,129).  
6.3 Zika Virus genome 
  The ZIKV genome is organized into single-stranded, positive-sense RNA that encodes a 3423 
amino acid polyprotein containing all of the viral proteins(130). The structural proteins include the viral 
capsid (C), precursor membrane (prM), and envelope (E) and are responsible for forming the virus particles. 
The non-structural proteins (NS1-5) are responsible for viral replication and host immune evasion(130) and 
include the NS1, which appears to be primarily involved in immune evasion (131-133), NS2A (replication, 
assembly), NS2B, which is the membrane-associated cofactor for the viral protease, NS3, which contains 
an N-terminal protease domain and a C-terminal helicase domain, NS4A (replication, assembly), NS4B 
(assembly), and NS5 which serves as the viral RNA-dependent RNA-polymerase (RdRp) as well as 
possessing methyltransferase activity(5,130). 
6.4 Zika Virus life cycle 
Many process in the ZIKV life cycle remain unclear. Studies have suggested that ZIKV may attach 
to host cells via interactions between glycosylated Envelop protein and glycosaminoglycans (GAGs) on the 
Figure 6.1. Genome organization of the ZIKV. The NS2B/NS3 protease is responsible for cleaving the viral polyprotein 
in five locations, as indicated by the black arrows. Blue arrows indicate sites of host protease cleavage. Arginine is a 
conserved residue in the P1 position, followed by a small, flexible residue in the P1’ position.  
 46  
 
 
 
cell surface (134,135). This mechanism is employed by other flaviviruses such as dengue, yellow fever, 
West Nile, and Japanese encephalitis (134). However, heparan sulfate, a cellular attachment receptor for 
multiple flaviviruses, does not appear to serve as the receptor for ZIKV(136). Conversely, the TAM 
receptor Axl has been shown to serve as the receptor for ZIKV on human glial cells(137); TAM receptors 
are not required for ZIKV infection in mice, however (138). Following attachment to the host receptor, 
ZIKV may be internalized through clathrin-mediated endocytosis upon which the virions are trafficked to 
Rab5+ endosomes(137).  
Presumably, ZIKV replicates in a similar manner to other flaviviruses (Figure 6.2) in which 
replication and assembly would occur in the following steps: 1) The genome is translated into a polyprotein 
in the cytoplasm of infected cells(130); 2) the polyprotein then is cleaved by the viral NS2B/NS3 protease, 
Figure 6.2. General Lifecycle of Flaviviruses. 1) Receptor-mediated endyocytosis of virus particle. 2) Fusion of 
virus and host membrane. 3) Genome release. 4) Translation of viral RNA and polyprotein processing. 5) Replication 
of the viral genome. 6) Viral assembly or new translation cycle. 7) Viral maturation by cleavage of prM to M. 8) 
Exocytosis of new virions. The figure is adapted from Fernandez-Garcia et. al. (5).  
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along with host proteases such as signalase and furin(139);  3) the viral NS5 RdRp creates a complimentary 
minus-strand which then serves as a template for the synthesis of new genomic RNA(140); 4) new virions 
are assembled in the ER and mature in the Golgi (141-146); 5) mature virions are released via exocytosis(5).  
6.5 Zika virus vaccine development 
 Currently no vaccine exists to prevent ZIKV infections. Strategies against other flaviviruses have 
been employed to develop a vaccine against ZIKV. In particular, it has been shown that antibody responses 
against the E glycoprotein protects animals and humans against flaviviruses(147-150). Recently, two 
groups have reported lipid nanoparticle encapsulated modified mRNA vaccines encoding the prM-E genes 
to be protective against ZIKV challenge in mice up to 18 weeks(151), and up to 5 weeks in non-human 
primates(152).  The mRNA vaccine has entered phase I and II human clinical trials (151). Other ZIKV 
vaccination strategies that have entered human clinical trials as of April, 2017 are DNA vaccines targeting 
the prM-E genes, inactivated virus, and a viral vector (153-155).  
6.6 Zika virus antiviral drug targets 
 Potential drug targets of ZIKV include the NS3 protease and helicase, NS5 polymerase and 
methytransferase, E glycoprotein, capsid protein, and the NS4B(156). The most promising drug targets are 
the NS3 protease and the NS5 polymerase. NS3 protease inhibitors will be discussed in section 6.7. 
The flaviviral NS5 polymerase is essential for the viral life and does not have a homologous 
eukaryotic protein, making it an attractive drug target(156). Furthermore, the success of polymerase 
inhibitors against HCV and HIV demonstrate the potential success of this strategy(157). Recently, the ZIKV 
NS5 RNA-dependent RNA polymerase (RdRp) has been crystallized to facilitate structure-based drug 
design(158). In addition, an assay using purified ZIKV NS5 RdRp has been developed to evaluate potential 
inhibitors (159,160). Sofosbuvir, a hepatitis C virus nucleoside inhibitor, 2’-C-methyl- and 2’-C-ethynyl-
substituted derivatives, and a non-nucleoside small-molecule, DMB213, have all been identified as 
potential inhibitors of the ZIKV NS5 RdRp (159-161). The structure of the methyltransferase domain of 
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the NS5 protein has also been solved; sinefungin and a Dengue virus inhibitor have been suggested as 
potential inhibitors of the ZIKV NS5 methyltransferase (162,163). 
Finally, the ZIKV NS3 helicase structure has been solved by x-ray crystallography and may provide 
a starting point for structure-based design of NS3 helicase inhibitors (164,165). 
6.7 Zika virus NS2B/NS3 protease and inhibitors 
 The ZIKV protease is comprised of the c-terminus of the membrane bound NS2B protein, which 
acts as a cofactor, and the protease domain of the NS3 protein. The active NS2B/NS3 protease, a serine 
protease with a catalytic triad of His51, Asp75, and Ser135, adopts a chymotrypsin-like fold and is 
responsible for cleaving the viral polyprotein in five locations:  capsid, NS2A/NS2B, NS2B/NS3, 
NS3/NS4A, and NS4B/NS5 (130,139,166,167). Proteolytic processing of viral polyprotein is an essential 
step in the viral lifecycle; inhibition of viral proteases has proven to be a successful strategy in fight HIV 
and HCV (157). Multiple structures of the ZIKV NS2B/NS3 protease have been solved in various 
conformational states, providing structural insights regarding protease activity, substrate recognition, and a 
basis for designing high-affinity compounds(139,166,168-170). When the NS2B cofactor is linked to the 
NS3 protease, the cofactor appears to adopt an “open” and “closed” conformation when in the absence and 
presence of substrate or inhibitor(139,169,170). However, when expressed as unlinked NS2B/NS3 
protease, the NS2B adopts a “closed” conformation even in the absence of substrate, suggesting that 
substrate or inhibitor binding does not induce a conformational change(166). The artificial peptide linker 
(G4SG4) may hinder substrate binding and alter protease activity, suggesting that unlinked protease should 
be used when designing and screening compounds (166,171).  
 Multiple groups have explored the NS2B/NS3 protease as a drug target (139,167,170-177). Recent 
studies have identified flavonoids (176), berberine based compounds (178), Aprotonin(167), 
bromocriptine(179), a substrate-based phosphonate inhibitor(174), as well as repurposed HCV NS3/NS4A 
protease inhibitors(175), and a potent inhibitor of the WNV and DENV NS2B/NS3 protease(171) as 
potential inhibitors of the NS2B/NS3 protease. In addition, potential allosteric inhibitors of the ZIKV 
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NS2B/NS3 protease have been identified (172,173). To date, the most potent NS2B/NS3 protease inhibitors 
reported have been peptide-based boronic acid inhibitors(139,177). However, cell permeability of the 
boronic acid inhibitors may present a significant challenge going forward.   
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CHAPTER 7: INCREASED ACTIVITY OF UNLINKED ZIKA VIRUS 
NS2B/NS3 PROTEASE COMPARED TO LINKED ZIKA VIRUS 
PROTEASE 
7.1 Introduction 
Zika virus (ZIKV) is a single-stranded, positive-sense flavivirus that is closely related to both West 
Nile (WNV) and Dengue viruses (DENV) (105). ZIKV, which is spread by the Aedes spp. mosquitoes, was 
discovered in 1947 (105,180). Since its discovery, ZIKV has diverged into two distinct lineages: African 
and Asian (107). ZIKV was previously thought to be a fairly mild infection, as most adults experience mild 
symptoms such as rash, fever, arthralgia, and conjunctivitis (111,112). However, the recent outbreak in the 
Americas in 2015 and 2016, which stems from the Asian lineage (108,109), suggests that some ZIKV 
infections have been associated with more severe complications. In addition, there is mounting evidence 
that ZIKV can be transmitted from an infected mother to fetus (181) which has led to increased incidence 
of birth defects that are associated with ZIKV. ZIKV has been shown to be causally linked to microcephaly 
in infants (113,114). In vitro and in vivo experiments have shown ZIKV causing damage in neural tissue 
(115-118). 
 Currently no vaccine or small-molecule inhibitor exists to treat ZIKV infections. However, recent 
studies have explored the NS2B/NS3 protease as a possible drug target (166,167,170,174,175,177,178,182) 
– a strategy that has been employed against other flaviviruses including DENV and WNV. Structure based 
approaches have led to the discovery of peptidomimetic boronate inhibitors which are highly active against 
the ZIKV NS2B/NS3 protease (IC50 = 250 nM) (139,177).   
A majority of the above studies (167,174-178,182) have used ZIKV protease constructs in which 
the NS2B cofactor is covalently linked to the NS3 protease domain via a Gly-Gly-Gly-Gly-Ser-Gly-Gly-
Gly-Gly (G4SG4) linker. However, based on their studies with a Nigerian ZIKV isolate (African lineage) 
Zhang et al. (166) and Phoo et al. (170) suggest that unlinked ZIKV protease, which is the naturally 
occurring form of the NS2B/NS3 protease, performs better than linked protease and should therefore be 
used when evaluating and designing anti-ZIKV protease compounds. A similar finding has also been 
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reported for the related DENV protease (183). To confirm these findings with an Asian lineage ZIKV strain, 
we expressed and purified unlinked and linked ZIKV protease from a Puerto Rico isolate. In addition, due 
to the close relationship between ZIKV, DENV, and WNV, we tested if highly active anti-DENV/WNV 
compounds (184-186) could be used as an advanced starting point for the discovery of ZIKV NS2B/NS3 
protease inhibitors.   
7.2 Materials and Methods 
7.2.1 Cloning 
Genbank no: KU501215.1, which corresponds to a Puerto Rico strain of ZIKV, was used to create 
a synthetic gene for the NS2B/NS3 protease. Based on an alignment with the DENV NS2B/NS3 protease 
(187), a construct containing residues 45 to 95 of the NS2B cofactor linked via a Gly4SerGly4 linker to the 
NS3 protease (residues 1 to 182) was submitted to Geneart (Life technologies) for custom gene synthesis.  
The resulting clone was received in a pMX vector and was digested with BsaI and XhoI to separate the 
ZIKV NS2B/NS3 protease insert from the plasmid. The free ZIKV NS2B/NS3 protease was ligated into a 
pSUMO vector, which contains a T7 promoter and an N-terminal His6-SUMO tag, and transformed into 
Escherichia coli BL21 Codon Plus (DE3) cells for protein expression. 
7.2.2 Site directed mutagenesis 
The original clone contained a proteolytic cleavage site at the junction of the NS2B cofactor and 
the Gly4SerGly4 linker. The clone containing this cleavage site is referred to as unlinked protease and 
corresponds the bZiPro as described by Phoo et al. (170).  
To avoid auto-proteolysis and create the linked protease, the last arginine residue of the NS2B 
cofactor before the G4SG4 linker was mutated to alanine (R95*A), and arginine 29 of the NS3 protease 
domain was mutated to glycine (R29G) as in Lei et al. 2016 (139). This linked construct corresponds to the 
gZiPro as described by Phoo et al. (170). Phusion High-fidelity PCR kit (New England Biolabs) was used 
to create the R95*A and R29G mutations. For the R95*A mutation, the forward primer was as follows: 5’ 
P-GT CCG CCT ATG GCG GGT GGT GGC 3’; the reverse primer was 5’ P-C ATC ATC TTC AAC CAG 
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GCT AAA ATC ACC G 3’. For the R29G mutation, the following primers were used: forward 5’ P-TT 
ATG ACC CGT GGC CTG CTG GGT AGC AC 3’; reverse 5’ P-C ACG ATA AAC ACC ATC GGT 
GGT TTC G 3’.  
7.2.3 Protein expression and purification 
Linked and unlinked protease were purified in the same manner as follows. Large scale protein 
expression was performed using a 2 L culture. The culture was grown to an OD600 of 1.0 at 37 °C in LB 
medium.  Protein expression was induced by addition of 0.6 mM Isopropyl β-D-1-thigactopyranoside 
(IPTG) and was carried out at 37 °C for 3 hours. The cells were harvested by centrifugation and lysed by 
French press.  The soluble fraction was purified using a Ni2+ affinity column (HisTrap™ HP, GE). The 
His6-SUMO tag was cleaved from the ZIKV protease by yeast SUMO Protease 1 and separated by a second 
round of Ni2+ affinity chromatography. A clean up round of size-exclusion chromatography (Superdex 200, 
GE) was performed to further purify the ZIKV protease. Pure ZIKV protease was concentrated in a buffer 
containing 20 mM Tris-HCl (pH 8.0), 150 mM NaCl, 5 mM β-mercaptoethanol, and 5% glycerol. Eluted 
fractions for each step of purification were analyzed by SDS-PAGE (15% w/v polyacrylamide) and 
Coomassie Brilliant Blue staining.  
7.2.4 Kinetic enzyme assay 
Purified linked and unlinked ZIKV protease were tested for enzymatic activity with a fluorometric 
enzyme assay. ZIKV protease was diluted in reaction buffer (10 mM Tris pH 8.5, 20% glycerol, 1 mM 
CHAPS) to a final concentration of 5 nM. Each reaction was initiated by addition of the substrate: L-
pyroglutamate-Thr-Gly-Lys-Arg-7-amido-4-methylcoumarin (Pyr-TGKR-AMC), purchased from 
Anaspec, Inc. The substrate corresponds to the P4-P1 residues of the NS2B/NS3 cleavage site. To determine 
the KM and Vmax, the substrate was serially diluted from 320 µM to 5 µM. The final reaction volume was 
50 μL. Enzymatic cleavage of the substrate results in release of 7-amino-4-methylcoumarin (AMC), which 
directly correlates with enzymatic activity and can be monitored by measuring AMC fluorescence. 
Measurements were carried out with a microplate reader (SpectraMax M5, Molecular Devices, Sunnyvale, 
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CA, USA); excitation: 360 nm and emission: 460 nm. Readings were taken every minute for 20 min; 
reactions were performed at 37°C. In order to convert RFU into µM, a standard curve of free AMC (9.72 
μM to 13 nM) was created. All data were plotted and analyzed with GraphPad Prism v. 6.07. 
7.2.5 Homology modeling and molecular dynamics simulations 
In lieu of a crystal structure for the Puerto Rico strain of ZIKV protease, homology models of linked 
and unlinked protease were created. Consensus models for the NS2B cofactor and the NS3 protease for the 
unlinked model were created separately using Schrӧdinger Prime (188). The model for the NS2B cofactor 
was built using 5LC0.pdb (chain B) (139) and 5T1V.pdb (chain A) as templates and the NS3 protease 
model was built using 5T1V.pdb (chain B), 5GJ4.pdb (chain H) (170), and 5LC0.pdb (chain A) as 
templates. They were then manually aligned in PyMOL (189) to create the non-covalent, unlinked protease 
complex. The linked protease model was built using 5LC0.pdb (chain A), 5GJ4.pdb (chains H and G), and 
Figure 7.1. Sequence alignment of unlinked and linked ZIKV protease to deposited 
structures 5GJ4.pdb, 5LC0.pdb, and 5T1V.pdb.  
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5T1V.pdb (chain A) as templates. The sequence alignments used to construct the models can be found in 
the supplementary information (Fig. 7.1).  
Each model was submitted to two separate 40 ns simulations. Molecular dynamics simulations 
were performed as previously described (87). The last 5 ns of each trajectory were used to analyze the 
RMSD and RMSF values for residues E37*-S41* (NS2B) and W50-V52, D75, D129-S135, Y150-V155, 
and Y161 (NS3 protease), which line the substrate binding pocket. An RMSD and RMSF value was 
calculated for each residue for all 5,000 frames to be used for statistical analysis (GraphPad Prism v. 6.07). 
7.2.6 Inhibition assay with compound A 
Known DENV and WNV protease inhibitor A (184) was tested for anti-proteolytic activity against 
linked and unlinked ZIKV protease. Protease was diluted to a final concentration of 5 nM in reaction buffer 
(10 mM Tris pH 8.5, 20% glycerol, 1 mM CHAPS). Compound A was serially diluted in DMSO and was 
incubated with diluted enzyme at 37°C for either 10 or 90 min prior to the addition of substrate. The final 
reaction volume was 50 µL. Substrate cleavage was monitored by an increase in fluorescence using a 
microplate reader: ex: 360nm; and em: 460 nm. Readings were taken every minute for 20 min. Data were 
plotted and analyzed with GraphPad Prism v. 6.07.  
7.3 Results and Discussion 
7.3.1 Expression and purification of linked and unlinked ZIKV protease 
The ZIKV NS2B/NS3 protease, which is responsible for cleavage of the viral polyprotein at five 
sites (see Fig. 6.1), has been explored as a potential drug target. In the current literature, reports of unlinked 
ZIKV protease as well as linked ZIKV protease are present (139,167,170,174-178,182). To explore 
potential differences between the two constructs, linked and unlinked ZIKV protease were cloned into 
Escherichia coli (E. coli) for protein expression and purification. Construction of the unlinked and linked 
protease clones are shown in figure 7.2.  
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Following overexpression, the soluble fraction of the cell lysate was purified as described in the 
methods section and shown in Figure 7.3. Following the second HisTrapTM column, the unlinked protease 
was analyzed by SDS-PAGE (Fig. 7.3) and showed evidence of three distinct bands – likely the result of 
autoproteolysis at the junction of NS2B Cofactor and G4SG4 linker. Cleavage at this site creates an unlinked 
NS2B/NS3 protease complex that interacts via non-covalent interactions. Continued purification of the 
NS2B/NS3 complex should be successful if the interactions between the NS2B cofactor and the NS3 
protease are strong enough. Size exclusion chromatography revealed the unlinked protease displayed one 
symmetrical peak eluted at 87.7 mL suggesting pure NS2B/NS3 complex (Fig 7.3). The peak corresponds 
to the MW (26 kDa) of a monomer NS2B/NS3 protease complex (Fig. 7.3). A small peak at 93.7 mL was 
apparent which may correspond to free NS2B cofactor (Fig. 7.3). When the size-exclusion fractions of the 
unlinked protease were analyzed by SDS-PAGE, three distinct bands were once again apparent (Fig. 7.2B) 
suggesting a mixture of both linked and unlinked protease, the majority being unlinked: NS2B/NS3 
C) 
A) 
B) 
Figure 7.2. A) Schematic diagram of the constructs for linked and unlinked ZIKV protease. NS2B cofactor residues 45-95 
were linked to NS3 protease residues 1-182 via a G
4
SG
4 
linker. An auto-proteolytic cleavage site between the NS2B cofactor 
and the G
4
SG
4 
linker (black arrow) creates the unlinked protease. Two mutations, R95*A and R29G (shown in red) prevent 
auto-proteolysis to produce linked protease.  B) Elution fractions from size-exclusion chromatography of unlinked protease. 
The top band at 29 kDa corresponds to linked protease, suggesting incomplete proteolysis. Unlinked protease is 
demonstrated by the middle band at 20 kDa (NS3 protease) and the lower band at ~14 kDa (NS2B). C) Elution fractions 
from size-exclusion chromatography of linked protease (29 kDa). The R95*A and R29G mutations prevent auto-proteolysis. 
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construct (29kDa), NS3pro + G4SG4 (20kDa), and NS2B cofactor (14.3kDa).The acidic nature of the NS2B 
cofactor (pI = 4.02) may be responsible for the high apparent MW (computed MW = 5.6 kDa).  
In addition to the unlinked protease, we mutated the original construct in two locations (R95*A 
and R29G), as described previously, to avoid auto-proteolysis and create linked protease. Expression and 
purification of linked protease was performed in the same manner as the unlinked protease. Analysis of the 
S200 elution fractions by SDS-PAGE for the linked protease show that the mutations successfully deterred 
autoproteolysis (Fig. 7.2C). The unlinked and linked proteases were then further analyzed for enzymatic 
activity.   
C) 
A) B) 
Figure 7.3. Protein purification scheme. A) Schematic diagram of the purification process for ZIKV protease. B) 
Uninduced and induced cells as well as cell lysate fractions and the 1st Ni2+ affinity column load, flow-through, wash and 
elution fractions. The full length fusion protein has an apparent MW of ~44 kDa. C) 2nd Ni2+ affinity column eluted fractions 
of unlinked protease containing the full length NS2B/NS3 protease (29 kDa), NS3 protease (20 kDa), and NS2B cofactor 
(14 kDa). D) Size-exclusion chromatogram of unlinked protease. The large peak at 87.7 mL corresponds to a monomer 
NS2B/NS3 protease. The small peak at 93.7 mL may correspond to free NS2B cofactor. 
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7.3.2 Characterization of Enzymatic Activity 
Following successful purification, unlinked and linked protease were tested for enzymatic activity. 
Fluorescent substrate (Pyr-TGKR-AMC), representing the P4-P1 residues of the NS2B/NS3 cleavage site, 
is cleaved enzymatically by ZIKV protease resulting in the conversion of 7-amido-4-methylcoumarin to 
free 7-amino-4-methylcoumarin (AMC). The release of AMC was monitored by fluorescence and directly 
correlates to enzymatic activity.  
As shown in Figure 7.4, the unlinked protease (kcat/KM = 19.3 x 103 M-1s-1) is roughly 6-fold more 
active than linked protease (kcat/KM = 3.3 x 103 M-1s-1). This difference in activity was maintained over time 
– the unlinked protease remained ~5-fold more active than the linked protease after a two hour incubation 
at 37°C (Fig. 7.5). The stability of the two enzymes, however, appeared to be comparable (Fig. 7.5).  
Interestingly, the R95*A and R29G mutations in the linked protease appeared to have an effect on 
substrate binding. The Michaelis-constant (KM) for unlinked and linked proteases were 49.25 μM and 61.03 
μM, respectively. In lieu of structural data for our linked and unlinked constructs, we created homology 
models of each construct and submitted each to two 40 ns molecular dynamics simulations. The unlinked 
model was built as a non-covalent complex between the NS2B cofactor and the NS3 protease. The linked 
model was built as a covalently linked NS2B/NS3 complex. At the end of the simulations, a striking 
 
Isolate kcat(s-1) KM(μM) kcat/KM(M-1s-1) 
Unlinked 0.95 ± 0.01 49.25 ± 1.91 19.3 x 103 
Linked  0.20 ± 0.02 61.03 ± 18.0 3.3 x 103 
Figure 7.4. Enzyme kinetics of unlinked and linked ZIKV protease. Kinetic parameters are represented as the mean ± 
standard error. Experiments were performed in triplicate. 
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difference between the two models was seen (Fig. 7.6). The C-terminus of the unlinked NS2B cofactor 
faced in an outward conformation away from the active site (Fig. 7.6). In contrast, the C-terminus of linked 
NS2B cofactor faces inward and occupies space over the substrate binding region when it is covalently 
linked to the NS3 protease (Fig. 7.6).  Steric hindrance of substrate binding by linked NS2B cofactor could 
be responsible for the difference in substrate binding affinity seen between unlinked and linked proteases 
(Fig. 7.6). This hypothesis has been proposed by the Luo and Kang groups based on solution NMR data on 
a Nigerian ZIKV isolate, which stems from the African lineage (166,170). Our homology modeling data of 
the Puerto Rico ZIKV isolate, which stems from the Asian lineage, aligns well with their hypothesis.  
Reduced flexibility of residues lining the substrate binding region in the linked protease compared 
to the unlinked may also be responsible for the substrate binding difference (Fig. 7.6). Average RMSD and 
RMSF for residues E37*-S41* (NS2B) and W50-V52, D75, D129-S135, Y150-V155, and Y161 (NS3 
protease) were calculated over the last 5 ns of two independent molecular dynamics simulations. Active 
site residues of the unlinked protease were significantly more flexible than linked protease (p<0.0001) (Fig. 
7.6), with average RMSD and RMSF values of 1.55 Å and 0.43 Å, respectively, compared to 1.32 Å and 
0.41 Å, respectively, for the linked protease (Fig. 7.6). The reduced flexibility of the active site residues in 
the linked NS2B/NS3 complex may reduce the ability of the linked enzyme to recognize and bind the 
substrate.   
Figure 7.5. Stability and activity of unlinked and linked protease over time. Left: Percent enzyme activity is plotted as a 
function of incubation time. Both unlinked and linked protease display comparable stability when exposed to physiological 
temperature (37°C). Right: Enzyme activity normalized relative to linked protease activity. Unlinked protease displays ~5-
fold greater activity up to two hours incubation at physiological temperature.   
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7.3.3 Inhibition of ZIKV by compound A 
Prior to the boronate inhibitor published by Lei et al. (139), there were no reports of any ZIKV 
protease inhibitor. However, the fact that the ZIKV is closely related to both DENV and WNV, and that 
the structures of these proteases are well conserved, led us to investigate known inhibitors of DENV and 
WNV proteases (184-186,190). Thus, we synthesized compound A (Fig. 7.7), a nanomolar inhibitor of the 
WNV protease (184), and evaluated its potency against the ZIKV protease. Interestingly, compound A 
inhibited both unlinked (IC50 = 1.06 μM) and linked protease (IC50 = 1.04 μM) with similar potency. 
Compound A remained active against the unlinked protease up to 90 minutes incubation (IC50 = 1.35 μM) 
(Fig. 7.7). An IC50 value against the linked protease after 90 minutes incubation could not be determined – 
the linked protease activity was very low after 90 minutes generating data could not fit a curve. Nonetheless, 
D75 
S135 
H51 
S135 
H51 
D75 
A) B) 
C) 
D) 
Figure 7.6. Structural comparison of unlinked and linked ZIKV PR. Homology models of unlinked and linked ZIKV 
protease were built using Schrӧdinger Prime and submitted to two 40 ns molecular dynamics simulations. The last frames 
of the simulations were used for analysis. A) Unlinked ZIKV NSB/NS3 protease. NS3 protease is shown in gray; NS2B 
cofactor is colored in a spectrum (blue = N-terminus; red = C-terminus). B) Linked ZIKV NS2B/NS3 protease. NS3 
protease is colored as light gray. NS2B cofactor is colored as a spectrum as in A). The covalent linker in B) occupies 
substrate binding region space. C) RMSD and RMSF values for residues lining the substrate binding region. RMSD and 
RMSF values were calculated over the last 5 ns of each simulation. The RMSD (angstroms) is plotted on the primary axis; 
Blue = unlinked, Red = linked. RMSF (angstroms) is plotted on the secondary axis; Green = unlinked, Magenta = linked. 
D) Average RMSD and RMSF values for residues lining the substrate binding region. RMSD values are plotted on the 
primary axis, and RMSF values are plotted on the secondary axis. Color scheme as in C). Significance, denoted by ****, 
was determined by student’s t-test (p<0.0001).  
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Compound A may be a good starting point for the development of ZIKV protease inhibitors, although 
activity and cellular permeability of such compounds may pose a significant challenge.  
 
7.4 Conclusion 
In conclusion, we report the successful expression, purification, and characterization of unlinked 
and linked ZIKV protease. The ZIKV isolate is from Puerto Rico, which stems from the Asian lineage and 
is relevant to the 2015-2016 outbreak in the Americas. Similar to what has been reported with the African 
lineage (Nigerian strain), we suggest that unlinked protease, which is the naturally occurring form of the 
protease, is superior to linked protease and should be used for evaluating and designing compounds against 
ZIKV protease. When comparing unlinked protease to linked protease, the unlinked protease is more active 
and binds substrate tighter than its linked counterpart. The weaker affinity for substrate shown by the linked 
protease may be a result of: 1) linked NS2B cofactor sterically inhibiting substrate binding and 2) reduced 
flexibility of the active site residues altering the ability of the linked enzyme to recognize and bind the 
substrate. Additionally, we report that a potent DENV/WNV protease inhibitor, compound A, was tested 
against ZIKV and found to have activity in the low micromolar range. Compound A may be a useful starting 
Compound A 
 
Isolate 
IC50 (μM) 
10 min 
IC50 (μM) 
90 min 
Unlinked  1.06 ± 0.34 1.35 ± 0.07 
Linked 1.04 ± 0.03 ND 
Figure 7.7. Structure and inhibitory activity of 
compound A against the ZIKV protease. IC
50 
values 
are reported as the mean ± one standard deviation of at 
least duplicate experiments.  
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point for the development of ZIKV protease inhibitors and demonstrates the potential for other flavivirus 
protease inhibitors to be repurposed to combat ZIKV infections.   
7.5 Author’s contributions 
The author, BDK, conducted the protein expression and purification experiments. The author also 
performed the site-directed mutagenesis, characterized the enzymatic activity of the purified enzyme, and 
characterized the inhibitory activity of compound A. Joshua Holcomb and Nicholas Spellmon assisted with 
protein expression and purification. Compound A was synthesized in the Laboratory of Biochemical 
Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, by Dr. 
Reuben Ovadia under the direction of Dr. Franck Amblard and Dr. Raymond Schinazi. 
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CHAPTER 8: FUTURE DIRECTION – ZIKA VIRUS 
 With the development of a biochemical assay to test compounds, the Kovari lab will aim to design 
compounds that will potently inhibit the ZIKV NS2B/NS3 protease. However, since the binding site of the 
NS2B/NS3 protease is very acidic, the compounds will need to be basic. A highly basic molecule poses 
significant challenges with regards to cell permeability. Structure based drug design as well as 
computational tools will be used to try to solve these problems. The long-term goal of this project is to 
develop potent, cell-permeable NS2B/NS3 protease inhibitors in order to prevent or clear Zika virus 
infections. 
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APPENDIX: THE L33F DARUNAVIR RESISTANCE MUTATION ACTS AS 
A MOLECULAR ANCHOR REDUCING THE FLEXIBILITY OF THE HIV-
1 PROTEASE 30S AND 80S LOOPS 
A1 Introduction 
The current standard of care for HIV, HAART, often employs a protease inhibitor (PI) containing 
regimen (191) but mutations in HIV-1 Protease (PR) that develop in treatment-experienced patients 
decrease the efficacy of all current PIs including DRV (191-193).  Thus, further analysis of key HIV-1 
protease resistance mutations is needed to develop more potent antivirals to combat drug resistance.  
Clinical isolates previously obtained from the Wayne State University Infectious Disease Clinic in 
Detroit, MI contain major drug resistance mutations L33F, I47V, I50V, I54M, L76V, V82I/F, and I84F as 
well as nonpolymorphicaccessory mutations L10V/G, V11I, I13V, K20T/R, L33I/M, K43T, F53L, A71L, 
T74P, and L89V.  These mutations confer resistance to all FDA approved PIs (http://hivdb.stanford.edu/) 
(194).  Molecular dynamics simulations with these isolates showed altered PR flap dynamics (88).  
To further investigate the role of the L33F mutation, we created a recombinant MDR769 L33F PR 
and performed X-ray crystallographic studies. L33F was initially identified as an accessory mutation to 
I54L/M, V32I + I47V, and I84V/I but is now recognized as a nonpolymorphic major drug resistance 
mutation (194,195). L33F is selected for in patients on a ritonavir pharmacokinetic boosted darunavir 
(DRV/r) regimen (193), is associated with DRV/r resistance (196), has greatly increased in prevalence since 
the year 2000 (197), and has direct influence on inhibitor-interacting residues (198). We hypothesize that 
reduced flexibility of the 30s and 80s loops due to molecular anchoring properties of L33F may contribute 
to drug resistance.  
A2 Materials and Methods 
A2.1 Protein Expression, Purification, and Crystallization 
The recombinant MDR769 L33F HIV-1 protease was expressed using a T7 promoter expression 
vector with Escherichia coli BL21 (DE3) as the host.  MDR769 L33F is based on the previously studied 
multi-drug resistant variant 769, MDR769, which contains the mutations Q7K, L10I, M36V, M46L, I54V, 
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I62V, L63P, A71V, V82T, I84V, L90M (199). MDR769 L33F contains all mutations seen in MDR769 as 
well as the additional mutation L33F. Purification strategies were carried out as previously described 
(200,201). Apo MDR769 L33F was crystallized using the hanging-drop vapor diffusion method. Two 
precipitant conditions produced crystals: (2.4M ammonium sulfate, 0.1 M MES, pH 6.2) and (2.4 M 
ammonium sulfate, 0.1 M HEPES, pH 6.8).  Co-crystallization methods were unable to produce high-
quality crystals; therefore, apo crystals were soaked for 19 hours in conditions matching the mother liquor 
in which they were formed, with the addition of DRV in molar excess (5 mM DRV, 5% DMSO).  The 
crystals were cryoprotected with 30% glucose and were flash frozen in liquid nitrogen. Data were collected 
at the LS-CAT facility, located within Argonne National Laboratory’s Advanced Photon Source.  
A2.2 Structure Determination, Refinement, and Analysis 
The structure of the apo L33F model was determined at a resolution of 1.50 Å. It was phased by 
molecular replacement (MR) using PHASER (202) with PDB entry 1TW7 as the initial search model.  
Refinement was performed using Phenix (203). Subsequent structures containing a PI were phased using 
the apo L33F structure as a search model.  The models were built in COOT (204).  After MR, ligands were 
added manually into the model after the protein was refined.  A round of refinement was performed with 
PDB-REDO (205) before deposition to the protein data bank (www.pdb.org). The final models were 
analyzed and validated with MolProbity (206). All images were created using PyMoL (189). Noncovalent 
interactions were identified using LigPlot+(207).  Hydrogen bonds were identified as donor-acceptor pairs 
with a cutoff distance of 3.2 Å; all distances were measured in PyMoL. The crystallographic data are shown 
in Table A1.   
A2.3 Molecular Dynamics Simulations  
Coordinates for Wild-Type PR (208) (3PHV.pdb), MDR769(199) (1TW7.pdb), and MDR769 
L33F (4YOB.pdb) were used for system preparation. Crystallographic waters were retained during the 
initial setup. The biologically active homodimer of the protease was used for the simulations. The systems 
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were placed in a TIP3P 5 Å water box and neutralized with magnesium chloride. MD simulations were 
performed as previously described(88) using NAMD(89) V. 2.9. 
Trajectories of the MD simulation were analyzed using Visual Molecular Dynamics(86) (VMD) 
V. 1.92. Residue RMSD values were calculated using the Timeline tool in VMD by analysis of the last 10 
ns of the simulation utilizing the frame corresponding to 30 ns as the reference frame. 
Parameters MDR769 L33F apo MDR 769 L33F:DRV Complex 
PDB Entry 4YOB 4YOA 
Data Collection:   
Space Group P41212 P41212 
Wavelength (Å) 0.979 0.97856 
Cell Constants (Å) a = 45.75  b = 45.75 c = 102.22 a = 45.47 b = 45.47 c =102.22 
Resolution Range (Å) 102.22-1.50 (1.68-1.50) 102.22-1.70 (1.90-1.70) 
Number of unique reflections 17,812 12,545 
Completeness (%) 99.1 (98.2) 99.9 (100) 
Redundancy 14.1 (14.5) 13.7 (14.2) 
Mean I/σ (I) 34.4 (3.4) 26.9 (4.2) 
Rmerge 0.046 (0.752) 0.049 (0.615) 
Refinement:   
Rwork (%) 17.6 19.01 
Rfree (%) 19.43 22.46 
Number of Atoms:   
Ligand  38 
Protease 782 784 
Solvent 134 71 
Average isotropic B factor (Å2):   
Ligand  93.94 
Protease 23.36 35.11 
Solvent 37.49 46.03 
RMSD bond length (Å) 0.007 0.014 
RMSD bond angle (°) 0.984 1.543 
Ramachandran plot:   
Allowed/generous/disallowed (%) 98/2/0 98/2/0 
 
Table A1. Crystallographic statistics. 
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A3 Results  
A3.1 Structural Features of the Residue 33 Environment 
The side chain of L33F extends 2.2 Å deeper into the hydrophobic pocket compared to wild-type 
(WT) L33 (Fig. A1) leading to increased hydrophobic interactions between L33F and the hydrophobic 
pocket. The hydrophobic pocket is defined by residues I13, I15, K20, A22, T31, M/V36, L38, I64, I66, 
V75, V77, N83, and I85 (Fig. A1B, C, and D). To visually identify changes in these residues, we aligned 
and superimposed the WT, MDR 769, and MDR 769 L33F structures. Although conformational and 
positional changes in these residues are seen between the WT and MDR 769 structures (Fig. A1B and C), 
the L33F mutation produces further alterations in many of these residues (Fig. A1D). The most notable 
change is in residue I13, which rotates to avoid steric clashes with L33F. Other significant changes due to 
A) B) 
C) D) 
Figure A1. Structural features of the residue 33 molecular anchor.  (A) Superposition of WT protease (green), 
MDR769 protease (magenta), and MDR769 L33F protease (yellow) apo structures. The 30s loop, which contains 
residue 33, is positioned between the 80s loop and the hydrophobic pocket. (B), (C), and (D) display WT, 
MDR769, and MDR769 L33F, respectively. Color schemes for (B), (C), and (D) are as shown in (A). L33F fills 
the hydrophobic pocket more completely than L33. The inset in panel (D) shows the 2F
o 
– F
c
 map for MDR769 
L33F contoured at 1σ. 
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the L33F mutation are noted in residues I15, K20, A22, V36, L38, I66, and N83. These changes lead to 
increased hydrophobic interactions in L33F compared to the WT and MDR 769 structures (Table A2).   
The MDR769 L33F structures show increased rigidity compared to the WT and MDR769 
structures.  Upon drug binding, L33 in the WT-DRV complex shifts 1.1 Å towards the active site and a 
hydrogen bond is formed between the backbone amide nitrogen of L33 and the backbone carbonyl of G78.  
Additionally, the side chains of residues I13, I15, M36, I66, and V75 are rotated, residues I15, K20, M36, 
L38, and V77 shift 0.4 Å, 1.2 Å, 2.3 Å, and 2.1 Å, respectively, into the hydrophobic pocket, and residues 
T31, V75, N83, and I85 shift 0.8 Å, 0.7 Å, 1.0 Å, and 0.5 Å away from the pocket.  Similar changes occur 
Table A2. Selected crystallographic statistics and molecular interactions. Top section: selected crystallographic 
statistics of deposited HIV-1 protease structures. Bottom section: First row: non-covalent interactions between residue 
33 (L/F) and hydrophobic pocket residues. Second row: non-covalent interactions between DRV and active site 
residues.  Interactions involving residue 33L/F were identified using the DimPlot script in LigPlot+; interactions between 
PR and DRV in the complexed structures were determined using LigPlot+. Mutations present in MDR769 reduce the number 
of non-covalent interactions with the hydrophobic pocket. Substitution of L33F restores the interactions between residue 33 
and the hydrophobic pocket and extends them beyond what is observed in the WT structures. Interactions between DRV and 
the active site are reduced by mutations present in MDR769 but are further reduced due to the molecular anchoring 
properties of the non-polymorphic L33F mutation. 
Structure 
Name 
WT 
Apo 
WT:DRV 
Complex 
MDR769 
Apo 
MDR769:DRV 
Complex 
MDR769 33F 
Apo 
MDR769 33F:DRV 
Complex 
PDB Code 3PHV 4LL3 1TW7 3SO9 4YOB 4YOA 
Resolution (Å) 2.7 1.95 1.3 2.87 1.5 1.7 
Rwork (%) 19.1 18.5 14.2 21.8 17.6 19.01 
Rfree (%) N/A 23.0 21.1 25.6 19.43 22.46 
 
Residue 33L/F 
Non-covalent  
Interactions 
 
30 27 24 23 32 31 
 
DRV:  
Non-covalent 
Interactions 
 
N/A 63 N/A 53 N/A 34 
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in the MDR769 structures upon drug binding. However, with the L33F mutation, minimal changes in 
conformation or position occur in either L33F or residues of the hydrophobic pocket upon drug binding in 
the MDR769 L33F structure.   
A3.2 L33F as a Molecular Anchor 
When the 30s loop (residues 29-35) of PR bears the L33F mutation,  flexibility of both the 30s and 
80s loops (residues 79-84) is decreased, likely through increased hydrophobic interactions. The 80s loop 
influences the S1/S1’ binding site (209), and the 30s loop lies between the 80s loop and the hydrophobic 
pocket (Fig. A1A).  In the WT-DRV complex, drug binding causes the 30s loop residues to shift, on 
average, 1.5 Å towards the active site compared to the WT apo structure (Fig. A2A).  In a similar fashion, 
the adjacent 80s loop residues also shift, on average, 2.0 Å towards the active site (Fig. A2A). Furthermore, 
residue 33L in the WT-DRV complex displays fewer noncovalent interactions compared to the WT apo 
A) B) 
C) 
Figure A2. L33F acts as a molecular anchor that restricts movement of the 30s and 80s loops.  
(A) Superposition of WT apo protease (green) and WT-DRV complex (cyan). (B) Superposition of 
MDR769 apo (magenta) and MDR769-DRV complex (blue). The 30s loop and 80s loop in (A) and 
(B) both shift with DRV bound. (C) Superposition of MDR769 33F apo (yellow) and MDR769 
L33F-DRV complex (red). L33F prevents movement of the 30s and 80s loops towards the active site 
as in the WT and MDR769 structures. The inset in (C) shows the 2F
o 
– F
c
 map for the 30s loop 
residues (D29-E35) contoured at 1σ. 
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structure (Table A2). Similar to the WT-DRV complex, the 30s and 80s loops of the MDR769-DRV 
complex shift 1.6 Å and 2.4 Å, respectively, towards the active site compared to the apo structure (Fig. 
A2B). Also, the number of noncovalent interactions is severely reduced in the MDR769 structures 
compared to the WT structures (Table A2). However, the 30s and 80s loops of the MDR769 L33F-DRV 
complex show minimal shifting upon drug binding; the only significant change is in residue P81, which 
shifts 0.4 Å into to the active site and puckers up when DRV is bound in the active site (Fig. A2C). In 
addition to the decreased flexibility of the 30s and 80s loops in the MDR769 L33F structures, the L33F 
mutation restores the noncovalent interactions with the hydrophobic pocket that were originally lost in the 
MDR769 complex. These restored interactions are also more extensively maintained than in the WT-DRV 
complex (Table A2). The decreased flexibility of both the 30s and 80s loops is likely due to enhanced 
anchoring by L33F via increased hydrophobic interactions within the hydrophobic pocket.   
Figure A3. Average RMSD of 30s and 80s loops for the last 10 ns of the MD simulation. Average RMSD was 
calculated for the 30s loop (residues 29-35) and 80s loops in VMD for the last 5000 frames of the simulation 
corresponding to the last 10 ns. 
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 To further assess the hypothesis of L33F acting as a molecular anchor, 40 ns MD simulations were 
performed. Differences in protein flexibility due to molecular anchoring of L33F should be more 
pronounced in apo PR compared to PI-complexed forms.  Therefore the RMSD of the 30s and 80s loops 
for both chains of apo WT, MDR769, and MDR769 L33F were analyzed over the last 10 ns. For WT PR, 
the average RMSD values of the 30s and 80s loops were 1.53 Å and 1.65 Å, respectively. The 30s loop of 
the MDR769 structure showed reduced flexibility compared to the WT structure with an RMSD of 1.34 Å 
whereas the 80s loop of the MDR769 showed similar flexibility compared to the WT (1.66 Å). Flexibility 
of the 30s and 80s loops in MDR769 L33F were further reduced compared to both WT and MDR769 
structures with the 30s loop displaying an RMSD of 1.27 Å and the 80s loop displaying an RMSD of 1.55 
Å (Fig. A3).  
A3.3 Reduced Flap Interactions and Altered Drug Conformation 
Previous work documented interactions between the 80s loop and the flap tips (210), their importance in 
substrate recognition and binding (211), and their influence on forming the  
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A) 
B) 
C) 
Figure A4. Reduced flap interactions due to L33F anchoring. (A) WT apo protease and WT protease complexed with 
DRV. The apo WT shows a 7.5 Å gap between P81 of the 80s loop and I50 of the flap producing an active site in the open 
conformation. When complexed with DRV, the flaps and active site close. (B) MDR769 apo protease and MDR769-DRV 
complex. Despite interactions between the 80s loop and flaps in the MDR769 protease, the flaps and active site display an 
open conformation. With DRV in the active site, the flexibility of MDR769 protease produces a closed active site. (C) 
MDR769 L33F apo PR and MDR769 L33F complexed with DRV bound resembles the WT apo structure in (A) with a 
large gap between residues I50’ and P81.  The gap between I50’ and P81 is maintained between the apo and complexed 
structures (5.8 Å and 5.9 Å, respectively) and is too large for interactions to occur. The active site and S1/S1’ subsite 
remain open. The inset in (C) shows the 2F
o 
– F
c
 map for DRV and the 80s loop in the L33F structure contoured at 0.5σ in 
order that the density around DRV is shown.   
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S1/S1’ subsite (209).  Thus, effects of the L33F mutation on the 80s loop and flap tips are possibly 
implicated in resistance development.   
 In the WT protease, the flexibility of the 80s loop and flaps produces favorable interactions 
allowing for proper formation of the S1/S1’ subsite. In the WT apo structure, a large 7.5 Å gap between the 
P81 of the 80s loop and I50 of the flap tips exists, preventing any interactions between the two (Fig. A4A).  
However, with DRV bound in the active site, the flaps close and the 80s loop shifts (2.0 Å) towards the 
active site which brings P81 within 3.7 Å of G49’ and T80 within 3.9 Å of I50’ (Fig. A4A).  These distances 
allow for favorable interactions between the flap and the 80s loop resulting in a closed active site, and more 
specifically, a properly formed S1/S1’ subsite (Fig. A4A).  As a result, DRV makes extensive noncovalent 
interactions with the residues lining the active site as indicated in Table A2.  
 Similar to the WT protease, the MDR769 protease displays considerable flexibility in the 30s and 
80s loops (Fig. A4B). The gap between residues P81 and I50’ in the MDR apo structure is not large 
compared to the WT (3.6 Å compared to 7.5 Å).  The flaps are in a “wide-open” conformation as reported 
previously (199), which leaves the active site open. In the MDR769-DRV complex, the flexibility of the 
30s and 80s loops (Fig. A2B) allows the active site to close (Fig. A4B). Even though the active site is 
closed, the number of noncovalent interactions between DRV and the active site is decreased, suggesting a 
slightly distorted active site (Table A2).  
 In the MDR769 L33F apo structure, the gap between the 80s loop and the flaps resembles the WT 
apo structure, producing an open active site and an open S1/S1’ subsite. The apo structure contains a 5.8 Å 
gap between P81 and I50’; this gap is smaller than the WT but still too large for any significant interactions 
to occur. In the L33F-DRV complex, P81 shifts 0.4 Å into the active site, but I50’ also shifts and rotates 
leaving a 5.9 Å gap which resembles the WT apo structure (Fig. A4C).  The 5.9 Å gap between P81 and 
I50’ leaves an open S1/S1’ subsite and also results in an open active site. The result is a severely reduced 
number of interactions between DRV and the active site compared to both the WT and MDR769 structures 
(Table A2). 
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Additionally, in the L33F-DRV complex, the side chains of P2, P1, and P1’ of DRV are rotated to 
compensate for the open S1/S1’ subsite (Fig. A4C) which alters the hydrogen-bonding network compared 
to the WT-DRV complex.  Previous reports have indicated a conserved hydrogen bonding network between 
DRV and backbone and side-chain atoms of residues D25, G27, D29, D30, D25’, and D30’ (212).  In the 
WT-DRV complex, the P2 bis-THF moiety, hydroxyl, and P2’ amine of DRV are responsible for formation 
of five hydrogen bonds with residues D25, D29, D30, D25’, and D30’ (data not shown). However, the 
L33F-DRV complex contains an expanded active site and S1/S1’ subsite which alters the conformation of 
P2, P1, P1’, and P2’of DRV. As a result, the P2 bis-THF moiety, hydroxyl, and P2’ amine of DRV form 
only three hydrogen bonds with residues D25N, D30, and D29’.  Additionally, the number of contacts 
decreased between the P1 group of DRV and the residues of the S1/S1’ subsite (Table A2).   
A4 Discussion 
The L33F mutation is selected  in patients receiving a DRV/r regimen (193), and is associated with 
reduced response to DRV/r treatment (194,196) as it has direct influence on the inhibitor-interacting 
residues (198). This report describes the effects of L33F on the structure of HIV protease as well as the 
effect it has on inhibitor recognition.   
Superposition of MDR 769 L33F with WT and MDR769 HIV-1 PR with and without DRV in the 
active site reveals altered conformation of the 30s and 80s loops. The larger side chain of L33F embeds 
further into the hydrophobic pocket than L33, the latter of which is present in both WT and MDR769 
structures (Fig. A1).  As a result, noncovalent interactions are increased in this region compared to the WT, 
causing the L33F to act as a molecular anchor.  MD simulations showed a clear reduction in flexibility of 
both the 30s and 80s loops for MDR769 L33F compared to both WT and MDR769. The results of these 
simulations support the hypothesis that L33F may play a role as a molecular anchor within HIV-1 protease. 
Enhanced molecular anchoring by the L33F mutation reduces the flexibility of the 30s and 80s 
loops, thereby inhibiting proper formation of the S1/S1’ subsite and keeping the active site in an open 
conformation in the MDR769 L33F-DRV complex (Figs. A2 and A4).  Conversely, in the WT and 
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MDR769 complex structures, DRV binding causes a shift in the 30s and 80s loops leading to formation of 
the S1/S1’ subsite and closing of the active site (Figs. A2 and A4s).  
The structure of the L33F DRV complex reported here shows the protease flaps in an open 
conformation. To date, all deposited structures of HIV PR L33F complexes have been solved in three 
different space groups: P212121, P61, and P41212. The majority of these HIV PR L33F DRV complexes have 
been solved with the flaps in a closed conformation. Other research groups such as the Schiffer group (213) 
and the Konvalinka group (214)  have previously reported L33F DRV complexes with the flaps in a closed 
conformation by solving the structures in P212121  (PDB ID: 4QY1) and P61  (PDB ID: 3GGU), respectively.  
In contrast, the Weber group (215) and this report describe the L33F DRV complex as a structure with open 
protease flaps when the structures were solved in P41212. The Weber group (215) (PDB ID: 4NPT) also 
utilized the inactivating mutation D25N to facilitate HIV PR expression, purification, and crystallization.  
 With specific regard to the L33F mutation, the Schiffer group (closed protease flaps) reports L33F 
may play a role in active site expansion (213). The Konvalinka group (closed protease flaps) suggests that 
L33F is possibly implicated in structural changes in the flap and flap hinge regions of PR. Despite structural 
and symmetry differences between the aforementioned and this report, our results regarding L33F as a 
molecular anchor are consistent with the previous reports by the the Schiffer and Konvalinka groups.  A 
key finding of our report is the influence of the L33F mutation on the open active site and on the S1/S1’ 
subsites through anchoring of the 30s and 80s loops independent of space group.  
A5 Conclusion 
In conclusion, for the first time we here report the molecular mechanisms by which the 
nonpolymorphic PR mutation L33F contributes to DRV resistance. The L33F mutation may contribute to 
resistance via two mechanisms: one, by restoring noncovalent interactions lost due to other primary 
mutations, and two, by further reducing interactions between DRV and active site residues. These findings 
may contribute to our overall understanding of drug resistance as well as future drug design strategies. We 
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propose that modifications to the P1/P1’ groups of existing PIs to fill the open S1/S1’ subsite might result 
in a greater response by patients who harbor the L33F mutation in HIV-PR.   
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 Noroviruses, which are the leading cause of acute gastroenteritis, cause an estimated 677 million 
infections and 213,000 deaths each year worldwide. Noroviruses are classified into seven genogroups (GI-
GVII); GI, GII, and GIV have been shown to be infectious in humans. However, GII noroviruses cause the 
majority of outbreaks (89%). No pharmacologic treatment or vaccine currently exists to treat or prevent 
norovirus infections.  
 Recently, the development of a norovirus replicon system, a murine model of norovirus infection, 
and the development of a biochemical protease assay have allowed for the design and development of 
norovirus inhibitors. However, the replicon and biochemical assay were developed with GI noroviruses. In 
this work, we have developed a system to design, evaluate, and develop inhibitors against GII noroviruses, 
which are responsible for the majority of outbreaks.  
 Using molecular dynamics simulations and other computational tools, we have shown that GII 
norovirus proteases behave comparably in solution with GI norovirus proteases in terms of protein 
flexibility as well as binding site solvent exposure, druggability, hydrophobicity, and volume. Therefore, 
we propose that protease inhibitors designed against either GI or GII norovirus proteases would be cross-
reactive with the other genogroup – a broad-spectrum norovirus protease inhibitor is likely feasible. In 
addition, we have developed a fluorescence based biochemical assay to design and evaluate protease 
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inhibitors against GII norovirus proteases, specifically a GII.4 norovirus protease. Using the biochemical 
assay and computational techniques, we also show that peptidomimetic inhibitors containing and aldehyde 
as an electrophilic warhead inhibit a GII.4 norovirus protease more potently than peptidomimetic inhibitors 
which contain an α,β-unsaturated ethyl ester Michael acceptor moiety as an electrophilic warhead.  
 Additionally, this work also explored the Zika virus (ZIKV) NS2B-NS3 protease as a potential 
drug target. ZIKV, an emerging flavivirus, was first discovered in 1947 but only recently caused an 
infectious outbreak of international concern in the Americas in 2015-2016. ZIKV diverged into two distinct 
lineages: African and Asian. The recent outbreak in the Americas, which has caused a total of 171,553 
confirmed infections over 48 countries, is associated with the Asian ZIKV lineage. Previously thought to 
be a mild infection, the recent outbreak, which is spread by the Aedes spp. mosquitoes, sexual-transmission, 
as well as vertical transmission from mother to fetus, is associated with more severe complications, the 
main concern being the rise in microcephaly cases. Depending on when ZIKV was contracted, 10-15% of 
pregnancies with laboratory confirmed ZIKV infection result in birth defects.  
 No vaccine or pharmacologic therapy yet exists to prevent or treat ZIKV infections. However, 
similar to other flaviviruses, the NS2B/NS3 protease has been proposed as a potential drug target. The 
NS2B protein, a membrane bound protein, exists acts as a cofactor for the NS3 protease during viral 
polyprotein cleavage. The structure of the ZIKV NS2B/NS3 protease was recently solved by X-ray 
crystallography, and a fluorescence based biochemical assay has been proposed in order to design, evaluate, 
and develop NS2B/NS3 protease inhibitors. The X-ray crystal structure and biochemical assay were 
developed with the NS2B cofactor covalently linked to the NS3 protease. In this work, we created the linked 
NS2B/NS3 protease, as well as unlinked NS2B/NS3 protease for comparison. The unlinked NS2B/NS3 
protease is roughly five-times more active than the linked NS2B/NS3 protease. Molecular dynamics 
simulations suggest that covalently linking the NS2B cofactor to the NS3 protease may reduce the substrate 
binding region flexibility as well as sterically hinder substrate binding. Therefore, we propose that unlinked 
NS2B/NS3 protease be used to design, evaluate, and develop ZIKV protease inhibitors.  
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 This work has resulted in valuable tools and structural insights that can aid the design and 
development of both norovirus and Zika virus protease inhibitors. In addition, the techniques described can 
be used to study other proteins, further understand protease behavior, and design new compounds.   
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